NO832662L - Fremgangsmaate for fremstilling av benzylidene-pyrrolo(2,1-b)quinazoliner og benzyliden-pyrido(2,1-b)quinazoliner - Google Patents
Fremgangsmaate for fremstilling av benzylidene-pyrrolo(2,1-b)quinazoliner og benzyliden-pyrido(2,1-b)quinazolinerInfo
- Publication number
- NO832662L NO832662L NO832662A NO832662A NO832662L NO 832662 L NO832662 L NO 832662L NO 832662 A NO832662 A NO 832662A NO 832662 A NO832662 A NO 832662A NO 832662 L NO832662 L NO 832662L
- Authority
- NO
- Norway
- Prior art keywords
- benzylidene
- pyrrolo
- quinazolin
- tetrahydro
- oxo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 115
- -1 N-pyrrolidinyl Chemical group 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 239000002244 precipitate Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- KRACOHAGYGQVHD-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 KRACOHAGYGQVHD-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KHSYJJDRXBNOJB-ZYHZCNJHSA-N (z)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)\C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 KHSYJJDRXBNOJB-ZYHZCNJHSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- KHSYJJDRXBNOJB-DDXPXLKJSA-N (E)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-4-oxobut-2-enoic acid Chemical compound C(C1=CC=CC=C1)=C1CCN2C1=NC=1C=C(C=CC1C2=O)NC(=O)/C=C/C(=O)O KHSYJJDRXBNOJB-DDXPXLKJSA-N 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- UAZGLBXIOXYDCH-UHFFFAOYSA-N 6-amino-3-benzylidene-1,2-dihydropyrrolo[2,1-b]quinazolin-9-one Chemical compound C=1C(N)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 UAZGLBXIOXYDCH-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- VDMHAWUSWQJULO-AORVBJBISA-N (z)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)C(\Cl)=C(\Cl)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 VDMHAWUSWQJULO-AORVBJBISA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- WJLPGYNGPNTBIF-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC(C=C1N=C23)=CC=C1C(=O)N2CCC3=CC1=CC=CC=C1 WJLPGYNGPNTBIF-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 229940071870 hydroiodic acid Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- HFACSUDMHFZPNH-UHFFFAOYSA-N 2-[(6-benzylidene-11-oxo-8,9-dihydro-7h-pyrido[2,1-b]quinazolin-3-yl)amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CCC3)=O)C=1N=C2C3=CC1=CC=CC=C1 HFACSUDMHFZPNH-UHFFFAOYSA-N 0.000 description 3
- PBSFAGJTPHHRJC-UHFFFAOYSA-N 2-[[3-(1,3-benzodioxol-5-ylmethylidene)-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=C2OCOC2=CC(C=C2C3=NC=4C(C(N3CC2)=O)=CC=C(C=4)NC(=O)C(=O)O)=C1 PBSFAGJTPHHRJC-UHFFFAOYSA-N 0.000 description 3
- DMBTWVHOQZVSDS-UHFFFAOYSA-N 2-[[3-[(2,3-diethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1OCC DMBTWVHOQZVSDS-UHFFFAOYSA-N 0.000 description 3
- GEUYLGJABIORJY-UHFFFAOYSA-N 2-[[3-[(2,3-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1OC GEUYLGJABIORJY-UHFFFAOYSA-N 0.000 description 3
- LKVUGKPJPTZOBF-UHFFFAOYSA-N 2-[[3-[(2,4-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1Cl LKVUGKPJPTZOBF-UHFFFAOYSA-N 0.000 description 3
- UBLCKFZYMAOCKO-UHFFFAOYSA-N 2-[[3-[(2,5-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC=C(OC)C(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 UBLCKFZYMAOCKO-UHFFFAOYSA-N 0.000 description 3
- SLCUXYPWMKSEPA-UHFFFAOYSA-N 2-[[3-[(2,5-dimethylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CC1=CC=C(C)C(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 SLCUXYPWMKSEPA-UHFFFAOYSA-N 0.000 description 3
- WEPMKVYSDIMXTO-UHFFFAOYSA-N 2-[[3-[(2-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1Cl WEPMKVYSDIMXTO-UHFFFAOYSA-N 0.000 description 3
- RPOGLPWITWCHBM-UHFFFAOYSA-N 2-[[3-[(3,4-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C(Cl)=C1 RPOGLPWITWCHBM-UHFFFAOYSA-N 0.000 description 3
- FRHSEIGXBNLYAV-UHFFFAOYSA-N 2-[[3-[(3,4-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 FRHSEIGXBNLYAV-UHFFFAOYSA-N 0.000 description 3
- SZZCIXHGVPQWBO-UHFFFAOYSA-N 2-[[3-[(3-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(Cl)=C1 SZZCIXHGVPQWBO-UHFFFAOYSA-N 0.000 description 3
- QBFGVAQCXZATSL-UHFFFAOYSA-N 2-[[3-[(3-ethoxy-2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1OC QBFGVAQCXZATSL-UHFFFAOYSA-N 0.000 description 3
- PHWSYQSQLWTJNO-UHFFFAOYSA-N 2-[[3-[(3-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 PHWSYQSQLWTJNO-UHFFFAOYSA-N 0.000 description 3
- ARIUSUGFLIILPK-UHFFFAOYSA-N 2-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 ARIUSUGFLIILPK-UHFFFAOYSA-N 0.000 description 3
- BNKINWXYQJDHNB-UHFFFAOYSA-N 2-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 BNKINWXYQJDHNB-UHFFFAOYSA-N 0.000 description 3
- KSXOIYBKUQNJQQ-UHFFFAOYSA-N 2-[[3-[(4-fluorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(F)C=C1 KSXOIYBKUQNJQQ-UHFFFAOYSA-N 0.000 description 3
- CXDUSFYTCZXLSS-UHFFFAOYSA-N 2-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 CXDUSFYTCZXLSS-UHFFFAOYSA-N 0.000 description 3
- QUDXSJVRUXRCGY-UHFFFAOYSA-N 2-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 QUDXSJVRUXRCGY-UHFFFAOYSA-N 0.000 description 3
- GRXPZBHDEUZKGE-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(3,4,5-trimethoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound COC1=C(OC)C(OC)=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 GRXPZBHDEUZKGE-UHFFFAOYSA-N 0.000 description 3
- WPPHHTMXAPXCNN-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[[3-(trifluoromethyl)phenyl]methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(C(F)(F)F)=C1 WPPHHTMXAPXCNN-UHFFFAOYSA-N 0.000 description 3
- RKWCYDJFBBFPPK-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylcarbamoyl]benzoic acid Chemical compound C=1C=C(C(N2CCC(C2=N2)=CC=3C=CC=CC=3)=O)C2=CC=1N(C)C(=O)C1=CC=CC(C(O)=O)=C1 RKWCYDJFBBFPPK-UHFFFAOYSA-N 0.000 description 3
- YFRKJLYZKQEDRH-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-3-oxopropanoic acid Chemical compound C=1C(NC(=O)CC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 YFRKJLYZKQEDRH-UHFFFAOYSA-N 0.000 description 3
- HPPZGMTVGBKWKF-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)NC=2C=C3C(C(N4CCC(C4=N3)=CC=3C=CC=CC=3)=O)=CC=2)=C1 HPPZGMTVGBKWKF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229910018954 NaNH2 Inorganic materials 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FFUVAASYSIBZOI-UHFFFAOYSA-N 2-[(3-benzylidene-1-methyl-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2-oxoacetic acid Chemical compound C12=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2C(C)CC1=CC1=CC=CC=C1 FFUVAASYSIBZOI-UHFFFAOYSA-N 0.000 description 2
- SHBPUHVRECMUEP-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]-2-ethylbutanoic acid Chemical compound C=1C(NC(=O)C(CC)(C(O)=O)CC)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 SHBPUHVRECMUEP-UHFFFAOYSA-N 0.000 description 2
- LMAMWZIXQGGDBO-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]-4,5-dichlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)C=C1C(=O)NC(C=C1N=C23)=CC=C1C(=O)N2CCC3=CC1=CC=CC=C1 LMAMWZIXQGGDBO-UHFFFAOYSA-N 0.000 description 2
- QBSLCVHMSREGSY-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]butanoic acid Chemical compound C=1C(NC(=O)C(C(O)=O)CC)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 QBSLCVHMSREGSY-UHFFFAOYSA-N 0.000 description 2
- VOUKGRJIXXTTSU-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-7-yl)amino]-2-oxoacetic acid Chemical compound C1CN2C(=O)C3=CC(NC(=O)C(=O)O)=CC=C3N=C2C1=CC1=CC=CC=C1 VOUKGRJIXXTTSU-UHFFFAOYSA-N 0.000 description 2
- DYJNQISPKZLULF-UHFFFAOYSA-N 2-[[3-[(2,4-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 DYJNQISPKZLULF-UHFFFAOYSA-N 0.000 description 2
- RLWBKCUMPIMBJE-UHFFFAOYSA-N 2-[[3-[(2,4-dimethylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CC1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 RLWBKCUMPIMBJE-UHFFFAOYSA-N 0.000 description 2
- CIBPDTIWUAWDHD-UHFFFAOYSA-N 2-[[3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=C(Cl)C=CC=C1Cl CIBPDTIWUAWDHD-UHFFFAOYSA-N 0.000 description 2
- DNMBGOVWSYMVKD-UHFFFAOYSA-N 2-[[3-[(2-ethoxy-3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CCOC1=C(OC)C=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 DNMBGOVWSYMVKD-UHFFFAOYSA-N 0.000 description 2
- IMAUOJAMYHPWBG-UHFFFAOYSA-N 2-[[3-[(2-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CCOC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 IMAUOJAMYHPWBG-UHFFFAOYSA-N 0.000 description 2
- OJFUPISDPSXBQL-UHFFFAOYSA-N 2-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 OJFUPISDPSXBQL-UHFFFAOYSA-N 0.000 description 2
- MWNWJKPQOUWCCC-UHFFFAOYSA-N 2-[[3-[(2-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 MWNWJKPQOUWCCC-UHFFFAOYSA-N 0.000 description 2
- UMGLHXFCPDHJQQ-UHFFFAOYSA-N 2-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 UMGLHXFCPDHJQQ-UHFFFAOYSA-N 0.000 description 2
- XOPNUAUTNUULAC-UHFFFAOYSA-N 2-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 XOPNUAUTNUULAC-UHFFFAOYSA-N 0.000 description 2
- ZQFRNNPCJKIHND-UHFFFAOYSA-N 2-[[3-[(4-aminophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=CC(N)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 ZQFRNNPCJKIHND-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- MCIJXABNBYSIDO-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(2,3,4-trimethoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound COC1=C(OC)C(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 MCIJXABNBYSIDO-UHFFFAOYSA-N 0.000 description 2
- GIXCUCWNEUULMY-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(2-propan-2-yloxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound CC(C)OC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 GIXCUCWNEUULMY-UHFFFAOYSA-N 0.000 description 2
- VUGXMAMNCVWYLF-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(2-propoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound CCCOC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 VUGXMAMNCVWYLF-UHFFFAOYSA-N 0.000 description 2
- JKNHSBHXBRMTDT-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(3-propoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound CCCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 JKNHSBHXBRMTDT-UHFFFAOYSA-N 0.000 description 2
- LNDKLDZZUAJYDU-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(4-propan-2-yloxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 LNDKLDZZUAJYDU-UHFFFAOYSA-N 0.000 description 2
- DDQKKPXMUZEUQZ-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(4-propoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound C1=CC(OCCC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 DDQKKPXMUZEUQZ-UHFFFAOYSA-N 0.000 description 2
- YBKLTQDKQNAVCS-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C)(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 YBKLTQDKQNAVCS-UHFFFAOYSA-N 0.000 description 2
- MUHRLMRVAZKOSF-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2-methyl-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 MUHRLMRVAZKOSF-UHFFFAOYSA-N 0.000 description 2
- HSJMNJGCGRTNED-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-3-oxo-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(=O)NC(C=1)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 HSJMNJGCGRTNED-UHFFFAOYSA-N 0.000 description 2
- SYRWUJONGWPIJG-UHFFFAOYSA-N 4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)NC(C=C1N=C23)=CC=C1C(=O)N2CCC3=CC1=CC=CC=C1 SYRWUJONGWPIJG-UHFFFAOYSA-N 0.000 description 2
- UYRFJDWFUWJAEY-UHFFFAOYSA-N 4-[(6-amino-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-3-ylidene)methyl]benzoic acid Chemical compound C=1C(N)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(C(O)=O)C=C1 UYRFJDWFUWJAEY-UHFFFAOYSA-N 0.000 description 2
- LQQUODSEBDWAAU-UHFFFAOYSA-N 4-[[6-(oxaloamino)-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-3-ylidene]methyl]benzoic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(C(O)=O)C=C1 LQQUODSEBDWAAU-UHFFFAOYSA-N 0.000 description 2
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004997 halocarbonyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- CLAJSVFEONNRRK-YWCRSASRSA-N (E)-4-[[3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound ClC1=C(C=C2CCN3C2=NC=2C=C(C=CC=2C3=O)NC(=O)/C=C/C(=O)O)C(=CC=C1)Cl CLAJSVFEONNRRK-YWCRSASRSA-N 0.000 description 1
- QDUOAIQYLWWLTB-YFDYNRBPSA-N (E)-4-[[3-[(2-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)/C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1Cl QDUOAIQYLWWLTB-YFDYNRBPSA-N 0.000 description 1
- WHKVGCHVPSXJEQ-DDXPXLKJSA-N (E)-4-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=C(C=C2CCN3C2=NC=2C=C(C=CC=2C3=O)NC(=O)/C=C/C(=O)O)C=CC=C1 WHKVGCHVPSXJEQ-DDXPXLKJSA-N 0.000 description 1
- IHBYHSRIEPVBNN-RTCNCHETSA-N (E)-4-[[3-[(3-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)/C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(Cl)=C1 IHBYHSRIEPVBNN-RTCNCHETSA-N 0.000 description 1
- QCXFAMMWHFCSGR-OWGWGLNUSA-N (E)-4-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC=2C3=O)NC(=O)/C=C/C(=O)O)C=CC=1 QCXFAMMWHFCSGR-OWGWGLNUSA-N 0.000 description 1
- SVLGYZXWPONDTK-JDBFBITMSA-N (E)-4-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)\C=C\C(O)=O)C=C4N=3)=O)CC2)=C1 SVLGYZXWPONDTK-JDBFBITMSA-N 0.000 description 1
- PVKBIQTVXABYTG-YFDYNRBPSA-N (E)-4-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)/C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 PVKBIQTVXABYTG-YFDYNRBPSA-N 0.000 description 1
- SCATXJHBILMQON-DDXPXLKJSA-N (E)-4-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC=2C3=O)NC(=O)/C=C/C(=O)O)C=C1 SCATXJHBILMQON-DDXPXLKJSA-N 0.000 description 1
- SXHCAUMFYJKPQB-JMUQMCQNSA-N (E)-4-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)\C=C\C(O)=O)=CC=C3C(=O)N2CC1 SXHCAUMFYJKPQB-JMUQMCQNSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZVNRKHDZOTXGCM-RDMUQYAASA-N (Z)-2,3-dichloro-4-[[3-[(2,4-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC(=C1)OC ZVNRKHDZOTXGCM-RDMUQYAASA-N 0.000 description 1
- PFGHRWMIWWHDOT-UQRIOQAHSA-N (Z)-2,3-dichloro-4-[[3-[(2,5-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C=C1)OC PFGHRWMIWWHDOT-UQRIOQAHSA-N 0.000 description 1
- NDEHXKUXVMMXCB-AYZZXAPOSA-N (Z)-2,3-dichloro-4-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC=C1 NDEHXKUXVMMXCB-AYZZXAPOSA-N 0.000 description 1
- ZZFATBRKRRHVQN-ABKQVKJQSA-N (Z)-2,3-dichloro-4-[[3-[(3,5-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C1)OC ZZFATBRKRRHVQN-ABKQVKJQSA-N 0.000 description 1
- LXJUOBCARDLESZ-FOBZWYGSSA-N (Z)-2,3-dichloro-4-[[3-[(3-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)C(\Cl)=C(\Cl)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(Cl)=C1 LXJUOBCARDLESZ-FOBZWYGSSA-N 0.000 description 1
- QVDINZLLAAYFBD-OTERHSDYSA-N (Z)-2,3-dichloro-4-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC1 QVDINZLLAAYFBD-OTERHSDYSA-N 0.000 description 1
- CYKHVLVPGVOYBH-NAXBVVOISA-N (Z)-2,3-dichloro-4-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)C(\Cl)=C(\Cl)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 CYKHVLVPGVOYBH-NAXBVVOISA-N 0.000 description 1
- XFGBFGUCBHFYNY-IAIIMBOFSA-N (Z)-2,3-dichloro-4-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 XFGBFGUCBHFYNY-IAIIMBOFSA-N 0.000 description 1
- KNZMPZFKPBVYSG-AYZZXAPOSA-N (Z)-2,3-dichloro-4-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C1 KNZMPZFKPBVYSG-AYZZXAPOSA-N 0.000 description 1
- NVVCMEYSTVZZSY-XVZSYGNWSA-N (Z)-2,3-dichloro-4-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 NVVCMEYSTVZZSY-XVZSYGNWSA-N 0.000 description 1
- VBWGUYUZOZXGIB-QEHZMELKSA-N (Z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[(4-propoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound C(CC)OC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C1 VBWGUYUZOZXGIB-QEHZMELKSA-N 0.000 description 1
- PAENXNHTKONBDW-XVZSYGNWSA-N (Z)-4-[(3-benzylidene-1-methyl-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound C12=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2C(C)CC1=CC1=CC=CC=C1 PAENXNHTKONBDW-XVZSYGNWSA-N 0.000 description 1
- NIPXCVUVVFPMBI-UHFFFAOYSA-N (Z)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2,3-dimethyl-4-oxobut-2-enoic acid Chemical compound C(C1=CC=CC=C1)=C1CCN2C1=NC=1C=C(C=CC1C2=O)NC(=O)C(=C(/C(=O)O)C)C NIPXCVUVVFPMBI-UHFFFAOYSA-N 0.000 description 1
- IHBYHSRIEPVBNN-NUWCYBIASA-N (Z)-4-[[3-[(3-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)\C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(Cl)=C1 IHBYHSRIEPVBNN-NUWCYBIASA-N 0.000 description 1
- SVLGYZXWPONDTK-ANPQNNLTSA-N (Z)-4-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)\C=C/C(O)=O)C=C4N=3)=O)CC2)=C1 SVLGYZXWPONDTK-ANPQNNLTSA-N 0.000 description 1
- JVFSXLHFYMWHLN-NAXBVVOISA-N (Z)-4-[[3-[(4-aminophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound C1=CC(N)=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 JVFSXLHFYMWHLN-NAXBVVOISA-N 0.000 description 1
- PVKBIQTVXABYTG-CEYALLMWSA-N (Z)-4-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C=1C(NC(=O)\C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 PVKBIQTVXABYTG-CEYALLMWSA-N 0.000 description 1
- NGXKCFRSELRFDR-GQHUUPTASA-N (Z)-4-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)\C=C/C(O)=O)=CC=C3C(=O)N2CC1 NGXKCFRSELRFDR-GQHUUPTASA-N 0.000 description 1
- CYIQDJCLFZBPBU-JMUQMCQNSA-N (e)-4-[[3-[(3-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)\C=C\C(O)=O)C=C4N=3)=O)CC2)=C1 CYIQDJCLFZBPBU-JMUQMCQNSA-N 0.000 description 1
- FRCMVHQZSQWKSN-QEHZMELKSA-N (z)-2,3-dichloro-4-[[3-[(2,3-diethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1OCC FRCMVHQZSQWKSN-QEHZMELKSA-N 0.000 description 1
- OYBUGLJQKDGRKS-AYZZXAPOSA-N (z)-2,3-dichloro-4-[[3-[(2,3-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1OC OYBUGLJQKDGRKS-AYZZXAPOSA-N 0.000 description 1
- VZCPBEVRIICSEL-IAIIMBOFSA-N (z)-2,3-dichloro-4-[[3-[(2-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CCOC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 VZCPBEVRIICSEL-IAIIMBOFSA-N 0.000 description 1
- NQAXPVDJEJQZFP-IAIIMBOFSA-N (z)-2,3-dichloro-4-[[3-[(3-ethoxy-2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1OC NQAXPVDJEJQZFP-IAIIMBOFSA-N 0.000 description 1
- OVVSCBDEJCRRAW-VLBLVXPCSA-N (z)-2,3-dichloro-4-[[3-[(3-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobut-2-enoic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1 OVVSCBDEJCRRAW-VLBLVXPCSA-N 0.000 description 1
- NUDLKBSLWUKSII-AYZZXAPOSA-N (z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[(2,3,4-trimethoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound COC1=C(OC)C(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 NUDLKBSLWUKSII-AYZZXAPOSA-N 0.000 description 1
- XMWRRBSMFFCLKT-PSGXUDGSSA-N (z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[(2-propan-2-yloxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound CC(C)OC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(\Cl)=C(\Cl)C(O)=O)=CC=C3C(=O)N2CC1 XMWRRBSMFFCLKT-PSGXUDGSSA-N 0.000 description 1
- ONZQPUBEYMTJHV-PEEILNHRSA-N (z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[(3-propan-2-yloxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound CC(C)OC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1 ONZQPUBEYMTJHV-PEEILNHRSA-N 0.000 description 1
- BEDAFTHTKVBVNI-PSGXUDGSSA-N (z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[(3-propoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound CCCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(\Cl)=C(\Cl)C(O)=O)C=C4N=3)=O)CC2)=C1 BEDAFTHTKVBVNI-PSGXUDGSSA-N 0.000 description 1
- CHLZHJKBZKPYGB-FOBZWYGSSA-N (z)-2,3-dichloro-4-oxo-4-[[9-oxo-3-[[3-(trifluoromethyl)phenyl]methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]but-2-enoic acid Chemical compound C=1C(NC(=O)C(\Cl)=C(\Cl)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(C(F)(F)F)=C1 CHLZHJKBZKPYGB-FOBZWYGSSA-N 0.000 description 1
- HQWWEILZEJWSDB-ZYHZCNJHSA-N (z)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-(dichloromethyl)amino]-4-oxobut-2-enoic acid Chemical compound C=1C(N(C(Cl)Cl)C(=O)\C=C/C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 HQWWEILZEJWSDB-ZYHZCNJHSA-N 0.000 description 1
- GNQRSBHDBYNVON-PKILARTOSA-N (z)-4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylamino]-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound C=1C(N(C(=O)C(\Cl)=C(\Cl)C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 GNQRSBHDBYNVON-PKILARTOSA-N 0.000 description 1
- FOTSRFOMIHRNHA-DVQHRWAUSA-N (z)-4-[[3-(1,3-benzodioxol-5-ylmethylidene)-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound C1=C2OCOC2=CC(C=C2C3=NC=4C(C(N3CC2)=O)=CC=C(C=4)NC(=O)C(\Cl)=C(\Cl)C(=O)O)=C1 FOTSRFOMIHRNHA-DVQHRWAUSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- TZMRZXDOGJFLRO-UHFFFAOYSA-N 2,2-dimethyl-3-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(C)(C)C(O)=O)C=C4N=3)=O)CC2)=C1 TZMRZXDOGJFLRO-UHFFFAOYSA-N 0.000 description 1
- WWODKBIESZZGHF-UHFFFAOYSA-N 2,2-dimethyl-3-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)(C)C(O)=O)=CC=C3C(=O)N2CC1 WWODKBIESZZGHF-UHFFFAOYSA-N 0.000 description 1
- IHCMUHGNRKTBRI-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-b]quinazolin-9-one Chemical compound N1C2=CC=CC=C2C(=O)N2C1CCC2 IHCMUHGNRKTBRI-UHFFFAOYSA-N 0.000 description 1
- YQYHCJZVJNOGBP-UHFFFAOYSA-N 2,3-dichloroprop-2-enoic acid Chemical compound OC(=O)C(Cl)=CCl YQYHCJZVJNOGBP-UHFFFAOYSA-N 0.000 description 1
- JBOWSWNNGUURSJ-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-(dichloromethyl)amino]-2-oxoacetic acid Chemical compound C=1C(N(C(Cl)Cl)C(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 JBOWSWNNGUURSJ-UHFFFAOYSA-N 0.000 description 1
- JEHBDYVUYRINTL-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-ethylamino]-2-oxoacetic acid Chemical compound C=1C(N(C(=O)C(O)=O)CC)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 JEHBDYVUYRINTL-UHFFFAOYSA-N 0.000 description 1
- MUGVVSMRRYJDNT-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylamino]-2-oxoacetic acid Chemical compound C=1C(N(C(=O)C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 MUGVVSMRRYJDNT-UHFFFAOYSA-N 0.000 description 1
- UOMFOUMWBNQITD-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]-3,4,5,6-tetrachlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(=O)NC(C=C1N=C23)=CC=C1C(=O)N2CCC3=CC1=CC=CC=C1 UOMFOUMWBNQITD-UHFFFAOYSA-N 0.000 description 1
- BQBMEVCXRYEUGW-UHFFFAOYSA-N 2-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)carbamoyl]cyclohexene-1-carboxylic acid Chemical compound C1CCCC(C(=O)O)=C1C(=O)NC(C=C1N=C23)=CC=C1C(=O)N2CCC3=CC1=CC=CC=C1 BQBMEVCXRYEUGW-UHFFFAOYSA-N 0.000 description 1
- VULAERVDFXAZFF-UHFFFAOYSA-N 2-[(6-benzylidene-11-oxo-8,9-dihydro-7h-pyrido[2,1-b]quinazolin-3-yl)-methylamino]-2-oxoacetic acid Chemical compound C=1C(N(C(=O)C(O)=O)C)=CC=C(C(N2CCC3)=O)C=1N=C2C3=CC1=CC=CC=C1 VULAERVDFXAZFF-UHFFFAOYSA-N 0.000 description 1
- NPUKXEKXDCIBHL-XFXZXTDPSA-N 2-[[(3z)-3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]prop-2-enoic acid Chemical compound C=1C(NC(=O)C(=C)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2\C3=C/C1=C(Cl)C=CC=C1Cl NPUKXEKXDCIBHL-XFXZXTDPSA-N 0.000 description 1
- RRIZJDPCCMMPRB-UHFFFAOYSA-N 2-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound COC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C=4C(=CC=CC=4)C(O)=O)=CC=C3C(=O)N2CC1 RRIZJDPCCMMPRB-UHFFFAOYSA-N 0.000 description 1
- VSXPCWCJMUMZFZ-UHFFFAOYSA-N 2-[[3-[(3,5-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound COC1=CC(OC)=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 VSXPCWCJMUMZFZ-UHFFFAOYSA-N 0.000 description 1
- SPKYZPNMVVTCJD-UHFFFAOYSA-N 2-[[3-[(3-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound CCOC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C=5C(=CC=CC=5)C(O)=O)C=C4N=3)=O)CC2)=C1 SPKYZPNMVVTCJD-UHFFFAOYSA-N 0.000 description 1
- RXPGVLQBQCCLLA-UHFFFAOYSA-N 2-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C=5C(=CC=CC=5)C(O)=O)C=C4N=3)=O)CC2)=C1 RXPGVLQBQCCLLA-UHFFFAOYSA-N 0.000 description 1
- ZODGWMJVBPFBNZ-UHFFFAOYSA-N 2-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)C=4C(=CC=CC=4)C(O)=O)=CC=C3C(=O)N2CC1 ZODGWMJVBPFBNZ-UHFFFAOYSA-N 0.000 description 1
- WZPKMOJKGCQTQU-UHFFFAOYSA-N 2-[[3-[(4-methoxycarbonylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C1=CC(C(=O)OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(O)=O)=CC=C3C(=O)N2CC1 WZPKMOJKGCQTQU-UHFFFAOYSA-N 0.000 description 1
- WDVZTAIAYSQTRN-UHFFFAOYSA-N 2-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C=4C(=CC=CC=4)C(O)=O)=CC=C3C(=O)N2CC1 WDVZTAIAYSQTRN-UHFFFAOYSA-N 0.000 description 1
- SKPWQSILMBSEAU-UHFFFAOYSA-N 2-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]carbamoyl]benzoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)C=4C(=CC=CC=4)C(O)=O)=CC=C3C(=O)N2CC1 SKPWQSILMBSEAU-UHFFFAOYSA-N 0.000 description 1
- RJZJFXVZEQMQEQ-UHFFFAOYSA-N 2-[[3-[(4-nitrophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound C=1C(NC(=O)C(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C([N+]([O-])=O)C=C1 RJZJFXVZEQMQEQ-UHFFFAOYSA-N 0.000 description 1
- ZYJQVOSLGFQFRX-UHFFFAOYSA-N 2-[benzyl-(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-2-oxoacetic acid Chemical compound C=1C=C(C(N2CCC(C2=N2)=CC=3C=CC=CC=3)=O)C2=CC=1N(C(=O)C(=O)O)CC1=CC=CC=C1 ZYJQVOSLGFQFRX-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- FEVVAEBHBNFFLU-UHFFFAOYSA-N 2-methyl-3-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC(C)=C1 FEVVAEBHBNFFLU-UHFFFAOYSA-N 0.000 description 1
- UTJJTLMEWSZICX-UHFFFAOYSA-N 2-oxo-2-[(9-oxo-2,3-dihydro-1h-pyrrolo[2,1-b]quinazolin-6-yl)amino]acetic acid Chemical compound N1=C2CCCN2C(=O)C2=CC=C(NC(=O)C(=O)O)C=C21 UTJJTLMEWSZICX-UHFFFAOYSA-N 0.000 description 1
- QMKWXCZMOBXBGR-UHFFFAOYSA-N 2-oxo-2-[[9-oxo-3-[(3-propan-2-yloxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]acetic acid Chemical compound CC(C)OC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(O)=O)C=C4N=3)=O)CC2)=C1 QMKWXCZMOBXBGR-UHFFFAOYSA-N 0.000 description 1
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AGULWIQIYWWFBJ-UHFFFAOYSA-N 3,4-dichlorofuran-2,5-dione Chemical compound ClC1=C(Cl)C(=O)OC1=O AGULWIQIYWWFBJ-UHFFFAOYSA-N 0.000 description 1
- KTYBPSOKYBVRRX-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylamino]-2-methyl-3-oxopropanoic acid Chemical compound C=1C(N(C)C(=O)C(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 KTYBPSOKYBVRRX-UHFFFAOYSA-N 0.000 description 1
- OBTNMWGJCRDMQI-UHFFFAOYSA-N 3-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylamino]-3-oxopropanoic acid Chemical compound C=1C(N(C(=O)CC(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 OBTNMWGJCRDMQI-UHFFFAOYSA-N 0.000 description 1
- YKRTXFDLMVDWHV-UHFFFAOYSA-N 3-[[3-[(2,5-dimethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound COC1=CC=C(OC)C(C=C2C=3N(C(C4=CC=C(NC(=O)CC(O)=O)C=C4N=3)=O)CC2)=C1 YKRTXFDLMVDWHV-UHFFFAOYSA-N 0.000 description 1
- XWPJBXXAJHVNLW-UHFFFAOYSA-N 3-[[3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C)(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=C(Cl)C=CC=C1Cl XWPJBXXAJHVNLW-UHFFFAOYSA-N 0.000 description 1
- FBJNPIPNSDGDLS-UHFFFAOYSA-N 3-[[3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C=1C(NC(=O)CC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=C(Cl)C=CC=C1Cl FBJNPIPNSDGDLS-UHFFFAOYSA-N 0.000 description 1
- AVKWLYMNFJOYKW-UHFFFAOYSA-N 3-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound COC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)(C)C(O)=O)=CC=C3C(=O)N2CC1 AVKWLYMNFJOYKW-UHFFFAOYSA-N 0.000 description 1
- HKFLMFIXVZOLGR-UHFFFAOYSA-N 3-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-methyl-3-oxopropanoic acid Chemical compound COC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)C(O)=O)=CC=C3C(=O)N2CC1 HKFLMFIXVZOLGR-UHFFFAOYSA-N 0.000 description 1
- JEXJNAOESKQEFG-UHFFFAOYSA-N 3-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(C)(C)C(O)=O)C=C4N=3)=O)CC2)=C1 JEXJNAOESKQEFG-UHFFFAOYSA-N 0.000 description 1
- ZETIOBVWXOHKKO-UHFFFAOYSA-N 3-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-methyl-3-oxopropanoic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)C(C)C(O)=O)C=C4N=3)=O)CC2)=C1 ZETIOBVWXOHKKO-UHFFFAOYSA-N 0.000 description 1
- DUGIUPZKUNKTON-UHFFFAOYSA-N 3-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)CC(O)=O)C=C4N=3)=O)CC2)=C1 DUGIUPZKUNKTON-UHFFFAOYSA-N 0.000 description 1
- KGEQIUSXTGGHMP-UHFFFAOYSA-N 3-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)CC(O)=O)C=C4N=3)=O)CC2)=C1 KGEQIUSXTGGHMP-UHFFFAOYSA-N 0.000 description 1
- OBRNPKZORVQNIC-UHFFFAOYSA-N 3-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C)(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 OBRNPKZORVQNIC-UHFFFAOYSA-N 0.000 description 1
- IWOOIJUQKRVKFU-UHFFFAOYSA-N 3-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-methyl-3-oxopropanoic acid Chemical compound C=1C(NC(=O)C(C(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 IWOOIJUQKRVKFU-UHFFFAOYSA-N 0.000 description 1
- AYIGNLTVZRFWHX-UHFFFAOYSA-N 3-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C=1C(NC(=O)CC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 AYIGNLTVZRFWHX-UHFFFAOYSA-N 0.000 description 1
- GXIJYGOQKHOCDI-UHFFFAOYSA-N 3-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)(C)C(O)=O)=CC=C3C(=O)N2CC1 GXIJYGOQKHOCDI-UHFFFAOYSA-N 0.000 description 1
- UQGHSTMNZICFRZ-UHFFFAOYSA-N 3-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)CC(O)=O)=CC=C3C(=O)N2CC1 UQGHSTMNZICFRZ-UHFFFAOYSA-N 0.000 description 1
- VXUDOBXUDAQBDN-UHFFFAOYSA-N 3-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2,2-dimethyl-3-oxopropanoic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)(C)C(O)=O)=CC=C3C(=O)N2CC1 VXUDOBXUDAQBDN-UHFFFAOYSA-N 0.000 description 1
- KKEDRNNQJOYYJA-UHFFFAOYSA-N 3-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-2-methyl-3-oxopropanoic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)C(C)C(O)=O)=CC=C3C(=O)N2CC1 KKEDRNNQJOYYJA-UHFFFAOYSA-N 0.000 description 1
- VQDUUZBTJCQQBM-UHFFFAOYSA-N 3-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)CC(O)=O)=CC=C3C(=O)N2CC1 VQDUUZBTJCQQBM-UHFFFAOYSA-N 0.000 description 1
- FPEOAWAPFIYQNB-UHFFFAOYSA-N 3-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-3-oxopropanoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)CC(O)=O)=CC=C3C(=O)N2CC1 FPEOAWAPFIYQNB-UHFFFAOYSA-N 0.000 description 1
- UCKPDEJTQRIACH-UHFFFAOYSA-N 3-piperidin-1-ylpropanoyl chloride Chemical compound ClC(=O)CCN1CCCCC1 UCKPDEJTQRIACH-UHFFFAOYSA-N 0.000 description 1
- URFBOPAPKHZWTJ-UHFFFAOYSA-N 4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)-methylamino]-4-oxobutanoic acid Chemical compound C=1C(N(C(=O)CCC(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 URFBOPAPKHZWTJ-UHFFFAOYSA-N 0.000 description 1
- CUTBXWBUCYWUEV-UHFFFAOYSA-N 4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-4-oxobutanoic acid Chemical compound C=1C(NC(=O)CCC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 CUTBXWBUCYWUEV-UHFFFAOYSA-N 0.000 description 1
- OGNKLKAUXSSJIH-UHFFFAOYSA-N 4-[(6-nitro-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-3-ylidene)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C=C1C2=NC3=CC([N+]([O-])=O)=CC=C3C(=O)N2CC1 OGNKLKAUXSSJIH-UHFFFAOYSA-N 0.000 description 1
- BUCRYSOGNBEAIN-UHFFFAOYSA-N 4-[[3-[(2,6-dichlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound C=1C(NC(=O)CCC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=C(Cl)C=CC=C1Cl BUCRYSOGNBEAIN-UHFFFAOYSA-N 0.000 description 1
- RUMIBQOFRHNJQS-UHFFFAOYSA-N 4-[[3-[(2-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound COC1=CC=CC=C1C=C1C2=NC3=CC(NC(=O)CCC(O)=O)=CC=C3C(=O)N2CC1 RUMIBQOFRHNJQS-UHFFFAOYSA-N 0.000 description 1
- MDIQYRNUVDRKHC-UHFFFAOYSA-N 4-[[3-[(3-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound COC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)CCC(O)=O)C=C4N=3)=O)CC2)=C1 MDIQYRNUVDRKHC-UHFFFAOYSA-N 0.000 description 1
- PZJKYZPIJNTIFS-UHFFFAOYSA-N 4-[[3-[(3-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound CC1=CC=CC(C=C2C=3N(C(C4=CC=C(NC(=O)CCC(O)=O)C=C4N=3)=O)CC2)=C1 PZJKYZPIJNTIFS-UHFFFAOYSA-N 0.000 description 1
- VQWZAYZCPBLFFU-UHFFFAOYSA-N 4-[[3-[(4-chlorophenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound C=1C(NC(=O)CCC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=C(Cl)C=C1 VQWZAYZCPBLFFU-UHFFFAOYSA-N 0.000 description 1
- SLRRVGJUYVOXFR-UHFFFAOYSA-N 4-[[3-[(4-ethoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(OCC)=CC=C1C=C1C2=NC3=CC(NC(=O)CCC(O)=O)=CC=C3C(=O)N2CC1 SLRRVGJUYVOXFR-UHFFFAOYSA-N 0.000 description 1
- QGBCYNPAFNSHKN-UHFFFAOYSA-N 4-[[3-[(4-methoxyphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C=C1C2=NC3=CC(NC(=O)CCC(O)=O)=CC=C3C(=O)N2CC1 QGBCYNPAFNSHKN-UHFFFAOYSA-N 0.000 description 1
- BVKAJRWCXFQFIU-UHFFFAOYSA-N 4-[[3-[(4-methylphenyl)methylidene]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1C=C1C2=NC3=CC(NC(=O)CCC(O)=O)=CC=C3C(=O)N2CC1 BVKAJRWCXFQFIU-UHFFFAOYSA-N 0.000 description 1
- JVGUYCGDKPBYRL-NNVVTTAXSA-N 4-[[6-[[(Z)-3-carboxy-2,3-dichloroprop-2-enoyl]amino]-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-3-ylidene]methyl]benzoic acid Chemical compound C(=O)(O)C1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C1 JVGUYCGDKPBYRL-NNVVTTAXSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IJCKSTBPPWDOKF-UHFFFAOYSA-N 5-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-3,3-dimethyl-5-oxopentanoic acid Chemical compound C=1C(NC(=O)CC(C)(CC(O)=O)C)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 IJCKSTBPPWDOKF-UHFFFAOYSA-N 0.000 description 1
- ZVIFPCSHAVZQKN-UHFFFAOYSA-N 5-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-5-oxopentanoic acid Chemical compound C=1C(NC(=O)CCCC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 ZVIFPCSHAVZQKN-UHFFFAOYSA-N 0.000 description 1
- SILQYTHEBWRGTB-UHFFFAOYSA-N 6-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-6-oxohexanoic acid Chemical compound C=1C(NC(=O)CCCCC(=O)O)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 SILQYTHEBWRGTB-UHFFFAOYSA-N 0.000 description 1
- IJGWDTRNPXDZBO-UHFFFAOYSA-N 6-nitro-2,3-dihydro-1h-pyrrolo[2,1-b]quinazolin-9-one Chemical compound N1=C2CCCN2C(=O)C2=CC=C([N+](=O)[O-])C=C21 IJGWDTRNPXDZBO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- IBTVIZMUFHLXEP-PSGXUDGSSA-N C(C)(C)OC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C1 Chemical compound C(C)(C)OC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C1 IBTVIZMUFHLXEP-PSGXUDGSSA-N 0.000 description 1
- IIJVJDUZAFBFPC-VLBLVXPCSA-N CC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C=C1)C Chemical compound CC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C=C1)C IIJVJDUZAFBFPC-VLBLVXPCSA-N 0.000 description 1
- DVHHFXCEDIQBKK-XFTLXAKLSA-N CC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC(=C1)C Chemical compound CC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC(=C1)C DVHHFXCEDIQBKK-XFTLXAKLSA-N 0.000 description 1
- WHKVGCHVPSXJEQ-UHFFFAOYSA-N COC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=CC=C1 Chemical compound COC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=CC=C1 WHKVGCHVPSXJEQ-UHFFFAOYSA-N 0.000 description 1
- SCATXJHBILMQON-UHFFFAOYSA-N COC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=C1 Chemical compound COC1=CC=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=C1 SCATXJHBILMQON-UHFFFAOYSA-N 0.000 description 1
- LHCRDECCWKXUSK-UFNLNPNBSA-N COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C1OC)OC Chemical compound COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=C(C1OC)OC LHCRDECCWKXUSK-UFNLNPNBSA-N 0.000 description 1
- QCXFAMMWHFCSGR-UHFFFAOYSA-N COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=CC1 Chemical compound COC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)C=C/C(=O)O)C=CC1 QCXFAMMWHFCSGR-UHFFFAOYSA-N 0.000 description 1
- 101100518413 Caenorhabditis elegans orc-2 gene Proteins 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- QAQXNVPQARFUFV-QZDBVLSGSA-N ClC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C(=CC=C1)Cl Chemical compound ClC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C(=CC=C1)Cl QAQXNVPQARFUFV-QZDBVLSGSA-N 0.000 description 1
- CHTVPFAWALOXFY-XWTMVWDTSA-N ClC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC(=C1)Cl Chemical compound ClC1=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC(=C1)Cl CHTVPFAWALOXFY-XWTMVWDTSA-N 0.000 description 1
- DPCJJXZMHGUHLU-XWTMVWDTSA-N ClC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC1Cl Chemical compound ClC=1C=C(C=C2CCN3C2=NC=2C=C(C=CC2C3=O)NC(=O)/C(=C(C(=O)O)/Cl)/Cl)C=CC1Cl DPCJJXZMHGUHLU-XWTMVWDTSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ULJYZBRGHIASEM-UHFFFAOYSA-N O=C1C2=CC=CC=C2N(CC(O)=O)C2N1C(N)CC2=CC1=CC=CC=C1 Chemical compound O=C1C2=CC=CC=C2N(CC(O)=O)C2N1C(N)CC2=CC1=CC=CC=C1 ULJYZBRGHIASEM-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VLXATHYNABSIQL-UHFFFAOYSA-N methyl 4-[(3-benzylidene-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-6-yl)amino]-4-oxobutanoate Chemical compound C=1C(NC(=O)CCC(=O)OC)=CC=C(C(N2CC3)=O)C=1N=C2C3=CC1=CC=CC=C1 VLXATHYNABSIQL-UHFFFAOYSA-N 0.000 description 1
- PIMBRDWYZDWMOH-UHFFFAOYSA-N methyl 4-[(6-nitro-9-oxo-1,2-dihydropyrrolo[2,1-b]quinazolin-3-ylidene)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C=C1C2=NC3=CC([N+]([O-])=O)=CC=C3C(=O)N2CC1 PIMBRDWYZDWMOH-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YPLIFKZBNCNJJN-UHFFFAOYSA-N n,n-bis(ethylamino)ethanamine Chemical compound CCNN(CC)NCC YPLIFKZBNCNJJN-UHFFFAOYSA-N 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av nye aminoderivater av benzyliden-pyrrolo-[2,1-b]kinazoliner og benzyliden-pyridof2,1-b]kinozoliner.
Oppfinnelsen tilveiebringer forbindelser med følgende generelle formel I
hvori
m betyr 0 eller 1;
n betyr 1 eller 2;
betyr:
a) hydrogen; -C^-alkenyl; eller C-^-Cg-alkyl, usubstituert eller substituert med en eller flere substituenter valgt blant halogen, hydroksy og fenyl; eller b) formyl; ellerC2_Cg-alkanoyl, usubstituert eller substituert med en eller flere substituenter valgt blant'
halogen, C^-C2_alkoksy og fenyl;
X fullfører en enkeltbinding eller det representerer:
a') en forgrenet eller rett C^-C^-alkylen- eller C2~ C12~
alkenylenkjede, usubstituert eller substituert med en eller flere substituenter valgt blant halogen og fenyl;
b') fenylen, usubstituert eller substituert med 1-4 halogenatomer;
c<1>) cykloheksylen eller cykloheksenylen;
1*2 betyr:
a") en gruppe - CE^ Z, der Z betyr klor, brom eller jod; b") en gruppe
hvori hver av R 7 og Rg uavhengig
kan være hydrogen eller C,-C,-alkyl eller R-, eller RQ
lb / o,
tatt sammen med nitrogenatomet, danner en usubstituert N-pyrrolidinyl-, morfolino- eller piperidinoring eller en N-piperazinylring som er usubstituert eller substituert med C-^-C^-alkyl eller med fenyl eller med C ^-C 2 -alkok sy karbonyl ;
c") karboksy eller C-, -C^-alkoksykarbonyl, usubstituert eller
substituert med en gruppe
der R 7 og Rg er som angitt ovenfor; R^ betyr et hydrogenatom eller en C-^-Cg-alkylgruppe ; idet hver av R^ , R,- og Rg uavhengig betyr et hydrogenatom eller et halogenatom, C-^-Cg-alkyl, halo-C-^-C^-alkyl, hydroksy, C-^-Cg-alkoksy,C^-C^-alkenyloksy, formyloksy, C2~Cg-alkanoyl-oksy, karboksy, C-^-C^-alkoksykarbonyl, hvori alkoksydelen er usubstituert eller substituert med en gruppe der R^ og Rg er som angitt ovenfor, nitro eller en gruppe
der hver av Rnog R,nuavhengig betyr et hydrogen-
atom, en C-^-Cg-alkylgruppe, formyl eller C2-Cg-alkanoyl;
eller hvilke som helst ved siden av hverandre stående R^, R,, og Rg, tatt sammen, danner en C-^-C-^alkylendioksygruppe.
Rammen for oppfinnelsen omfatter også de farmasøytisk akseptable salter av forbindelene med formel I, alle de mulige isomerer (f.eks. Z- og E-isomerer og optiske isomerer) og blandinger derav så vel som metabolitter og de metabolske forløpere av forbindelsene med formel I.
Alkyl-, alkenyl-, alkylen-, alkenylen-, halo-alkyl-, alkoksy-karbonyl-, alkenyloksy-, alkoksy-, alkanoyl- og alkanoyloksy-gruppene kan være forgrenede eller rettkjedede grupper. Nummereringen som benyttes for å identifisere posisjonen i forbindelsene med formel I er den konvensjonelle som vist i de følgende eksempler:
A) nar n = 1:
B) når n = 2:
En C^-C^-alkenylgruppe er f.eks. allyl eller 2-metylallyl.
En C-^-Cg-alkylgruppe er fortrinnsvis en C-^-C^-alkylgruppe, spesielt metyl, etyl, propyl og isopropyl.
Et halogen er f.eks. fluor, klor eller brom, fortrinnsvis fluor eller klor. En C-^-Cy-alkoksykarbonylgruppe er fortrinnsvis en C-^-C,--alkoksykarbonylgruppe og spesielt met-oksykarbonyl og etoksykarbonyl.
En C2_Cg-alkanoylgruppe er f.eks. acetyl, propionyl, butyryl, valeryl og isovaleryl, fortrinnsvis acetyl.
En halo-C^-C4-alkylgruppe er f.eks. en C-^-C^-alkylgruppe substituert med 1-3 halogenatomer, f.eks. klor, fluor og
brom, spesieltjer gruppen trifluormetyl.
En C^-Cg-alkoksygruppe er f.eks. en C-^- C^-alkoksygruppe, spesielt metoksy og etoksy.
En C^-C-j-alkylendioksygruppe er f.eks. metylendioksy og etylendioksy.
En forgrenet eller rett C^-C^2~alkylenkjede er fortrinnsvis en forgrenet eller rett C-^-Cg-alkylenkjede, spesielt f.eks.
En forgrenet eller rett C2_C^2-al^enYlen^je<^e er fortrinnsvis en forgrenet eller rett C2-Cg-alkenylenkjede, spesielt f.eks. -CH=CH-,
En C2-Cg-alkanoyloksygruppe er f.eks. en acetoksy, propionyl-oksy og butyryloksy, fortrinnsvis er den acetoksy.
Når en eller flere av R^, R7og Rg er en C-^-Cg-alkylgruppe, er alkylgruppen fortrinnsvis en C^-C^-alkylgruppe, spesielt metyl, etyl, propyl og isopropyl.
Når en eller flere av R^, R^, R^ og Rg er en C-^-Cg-alkyl-gruppe, er alkylgruppen fortrinnsvis metyl eller etyl.
Når en eller flere av R^, R<- og Rg er en C-^-Cg-alkoksygruppe, er alkoksygruppen fortrinnsvis metoksy, etoksy, propoksy og isopropoksy.
Mere foretrukne forbindelser ifølge oppfinnelsen er forbindelser med formel I, hvori
m er 1 ;
n er 1;
R^er hydrogen eller C-^-C^-alkyl, eventuelt usubstituert
eller substituert med fenyl;
X fullfører en enkeltbinding; eller X er C-^-Cg-alkylen eller C2_Cg-alkenylen, begge eventuelt substituert med opptil
1-3 kloratomer;
R~er piperidinometyl, morfolinometyl, (1-pyrrolidinyl)-metyl eller (1-piperazinyl)-metyl, hvori piperazinylringen evnetuelt er substituert med C^-C^-alkyl, fenyl eller med C^-C2-alkoksykarbonyl; eller R2er karboksy eller C-^-Cj--alkoksykarbonyl, eventuelt substituert med en N,N-dimetyl-amino- eller enN,N-dietylaminogruppe;
R^er hydrogen eller metyl;
idet hver av R^ , R og Rg uavhengig er hydrogen, fluor, klor, C-^-C2-alkyl, hydroksy, -alkoksy, acetoksy, karboksy eller hvilke som helst to ved siden av hverandre stående R^, Rj. og Rg, tatt sammen danner en metylendioksygruppe ;
samt farmasøytisk akseptable salter derav.
Eksempler på farmasøytisk akseptable salter er alle de med uorganiske baser, slik som natrium-, kalium-, kalsium- og aluminiumhydroksyder eller med organiske baser slik som lysin, trietylamin, trietanolamin, dibenzylamin, metylbenzyl-amin, tris-(hydroksymetyl)-aminometan, piperidin, N-etyl-piperidin, N,N-dietylamin'oetylamin, N-etylmorfolin, 8--fene-tylamin, N-benzyl-6-fenetylamin, N-benzyl-N,N-dimetylamin og andre akseptable organiske aminer, så vel som salter med uorganiske syrer, f.eks. saltsyre, hydrobromsyre, salpeter-syre og svovelsyre, og med organiske syrer slik som sitron-syre, vinsyre, maleinsyre, eplesyre, fumarsyre, metansulfon-syre og etansulfonsyre.
Eksempler på spesielt foretrukne forbindelser ifølge oppfinnelsen er: N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre;
N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinozolin-6-yl]-amino-oksoeddiksyre; N- [3 -(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl ]-amino-oksoeddiksyre; N- [3-(4-metoksy-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl ]-amino-oksoeddiksyre; N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl] -amino-oksoeddiksyre ; N- [3-(4-etoksy-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl ]-amino-oksoeddiksyre; N-[3-(4-fluor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl ]-amino-oksoeddiksyre; N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl]-amino-oksoeddiksyre; N- [3-(4-klor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2,3-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2-metoksy-3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2,5-dimetyl-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2,6-diklor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l^b]kinazolin-6-yl]-amino-oksoeddiksyre; (Z)-3 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre ; (E)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre;
(Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre; N-[3 -(2,4-diklor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl -amino-oksoeddiksyre;
N-[3-(2-klor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre;
N-[3 -(3-trifluormetyl-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2,3-dietoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(3,4,5-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3,4-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]amino-oksoeddiksyre; N-[3 -(4-kårboksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(3,4-metylendioksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-(6-benzyliden-ll-okso-6,7,8,9-tetrahydro-llH-pyrido-[2,l-b]kinazolin-3-yl)-amino-oksoeddiksyre; N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl-eddiksyre;
3-benzyliden-6-N-(3-morfolino-propionyl)-amino-1,2,3,9-tetrahydro-pyrrolof 2,l-b]kinazolin-9-on;
3-benzyliden-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolof 2,1-b]kinazolin-9-on ;
og farmasøytisk akseptable salter derav, spesielt natirum-, trietanolamin- og tris-(hydroksymetyl)-aminometansaltene og hydrokloridene av de basiske estere, (f.eks. de med 2-dietyl-aminoetanol) og C^-Cg-alkylestere derav, spesielt metyl-, etyl-, isopropyl- og n-butylestrene.
Forbindelsene med formel I kan fremstilles ved en prosess som omfatter:
a) å omsette en forbindelse med formel II
hvori
n, R^, R^ , R^ , R,, og Rg er som angitt ovenfor, med en forbindelse med formel III
hvori
X og R2er som angitt ovenfor og Y betyr et halogenatom, hydroksy eller en gruppe -OCOORg, hvori Rg betyr benzyl, fenyl eller C-^-Cg-alkyl, for således å oppnå en forbindelse med formel I hvori m er 1, eller
b) å omsette en forbindelse med formel II som angitt ovenfor med en forbindel med formel IV
hvori
X er som angitt ovenfor, bortsett fra en enkeltbinding, for
å oppnå en forbindelse med formel I, hvori m er 1, R2 er karboksy, og X er som angitt ovenfor, bortsett fra en enkeltbinding; eller
c) å omsette en forbindelse med formel II som angitt ovenfor med en forbindelse med formel V
hvori
X, Z og R2er som angitt ovenfor, for å oppnå en forbindelse
med formel I hvor m er 0; eller
d) å omsette en forbindelse med formel VI
hvor
m, n, X, R^, R^og R^er som angitt ovenfor eller et salt derav, med et aldehyd med formelen VII
hvori
R^, R,- og Rg er som angitt ovenfor; og hvis ønskelig, omdanning av en forbindelse med formel I til en annen forbindelse med formel I og/eller hvis ønskelig, omdanning av en forbindelse med formel i til et farmasøytisk akseptabelt salt og/ eller hvis ønskelig, omdanning av et salt til en fri forbindelse og/eller hvis ønskelig, å separere en blanding av isomerer i de enkelte isomerer.
I en forbindelse med formel III er Y fortrinnsvis klor, brom, hydroksy eller en gruppe -OCCXX^H,.; og helst er den klor eller brom.
Reaksjonen mellom en forbindelse med formel II og en forbindelse med formel III, hvori X og R2er som angitt ovenfor og Y er halogen, fortrinnsvis klor eller brom, eller en gruppe -OCOORg, der R^er som angitt ovenfor, kan f.eks. gjennomføres i et organisk oppløsningsmiddel slik som diklor etan, diklormetan, kloroform, dimetylformamid, dimetylacetamid i nærvær av en base slik som pyridin, trietylamin, N-metylpiperidin, N,N-dimetylanilin ved.en temperatur som varierer mellom ca. 0°C og ca. 100°C og fortrinnsvis mellom ca. 0°C og ca. 40°C.
Reaksjonen mellom en forbindelse med formel II og en forbindelse med formel III, der X og R2er som angitt ovenfor og Y er hydroksy, kan f.eks. gjennomføres i nærvær av et dehydratiseringsmiddel slik som N,N-karbonyldiimidazol, N,N-dicykloheksylkarbodiimid, N-hydroksypiperidin, N-hydroksy-succinimid i et organisk oppløsningsmiddel slik som dimetylformamid, dimetylacetamid, diklormetan, dioksan, tetrahydrofuran, acetonitril ved en temperatur som varierer mellom 0°C og ca. 120°C, fortrinnsvis mellom romtemperatur og ca. 80°C. Reaksjonen mellom en forbindelse med formel II og en forbindelse med formel IV kan f.eks. gjennomføres i et oppløsningsmiddel slik som diklormetan, dikloretan, kloroform, tetrahydrofuran, dimetylformamid, dimetylacetamid ved en temperaturer som varierer mellom romtemperatur og ca. 100°C og fortrinnsvis mellom romtemperatur og ca. 70°C.
Reaksjonen mellom en forbindelse med formel II og en forbindelse med formel V kan f.eks. gjennomføres i nærvær av en base slik som Na2C03, K^ CO^, NaH og NaNH2i et oppløsnings-middel slik som dimetylformamid, dimetylacetamid, dioksan, tetrahydrofuran og blandinger derav ved en temperatur som varierer mellom romtemperatur og ca. 100°C.
Foretrukne salter av en forbindelse med formel VI er de med uorganiske baser slik som natrium- og kaliumsalter så vel som salter med uorganiske syrer, f.eks. saltsyre, hydrobromsyre, hydrojodsyre og svovelsyre.
Reaksjonen mellom en forbindelse med formel VI eller et salt derav med et aldehyd med formel VII gjennomføres fortrinnsvis i nærvær av et basisk kondensasjonsmiddel slik som
natriumetoksyd, natriummetoksyd, natriumhydrid, natrium-
amid eller natriumhydroksyd i et oppløsningsmiddel valgt f.eks. blant metanol, etanol, isopropanol, dioksan, vann og blandinger derav, ved temperaturer som fortrinnsvis ligger i området mellom ca. 0°C og ca. 120°C.
En forbindelse med formel I kan som angitt ovenfor omdannes til en annen forbindelse med formel I ved kjente metoder, f.eks. kan en C-^-C^-alkoksykarbonylgruppe omdannes til en fri karboksygruppe ved hydrolyse, f.eks. basisk hydrolyse, f.eks. ved bruk av natrium- eller kaliumhydroksyd, i et oppløsningsmiddel slik som vann, dioksan, dimetylformamid eller en lavere alifatisk alkohol og blandinger derav, og ved å arbeide ved temperaturer som ligger innen området romtemperatur til ca. 100°C; den samme reaksjon kan også gjennomføres f.eks. ved behandling med litiumbromid i dimetylformamid ved en temperatur over 50°C eller ved behandling med saltsyre eller hydrobromsyre eller hydrojodsyre eller svovelsyre i eddiksyre ved en temperatur over 50°C.
En fri karboksygruppe kan omdannes til en C-^-C^-alkoksy-karbonylgruppe som eventuelt er substituert med en -NcT~^7-
8 gruppe, hvoriR^og Rg er som angitt ovenfor, ved konvensjonelle metoder, f.eks. ved å omsette syren med et egnet C-^-Cy-alkylalkohol i nærvær av en Lewis-syre slik som gass-formig saltsyre, 98 %-ig svovelsyre, bortrifluorideterat,
ved en temperatur som varierer fra romtemperatur til tilbake-løpstemperaturen.
Alternativt kan forestringen av en fri karboksygruppe til
en forbindelse med formel I gjennomføres ved omdanning av karboksylsyren til det tilsvarende halogenkarbonyl-, fortrinnsvis klorkarbonylderivat, ved omsetning f.eks. med det ønskede syrehalogenid, f.eks. oksalylklorid, tionylklorid, PCl^, PCl^eller POCl^, enten i fravær av oppløsningsmidler eller i et inert organisk oppløsningsmiddel slik som benzen, toluen, xylen, dioksan, dikloretan, metylenklorid eller tetrahydrofuran ved en temperatur som fortrinnsvis ligger
innen området ca. 0°C til ca. 120°C og deretter å omsette det resulterende halogenkarbonylderivat med en egnet C-^-C^-alkylalkohol i et inert oppløsningsmiddel slik som benzen, toluen, xylen, dioksan, dikloretan, metylenklorid eller tetrahydrofuran, ved temperaturer som varierer mellom ca.
0°C og ca. 120°C, fortrinnsvis i nærvær av en base slik som trietylamin eller pyridin.
Videre kan en forbindelse med formel I hvori R, er hydrogen, omdannes til en forbindelse med formel I, der R-^er C^-C^-alkenyl eller C-^-Cg-alkyl, eventuelt substituert som angitt ovenfor, f.eks. ved omsetning med et egnet -C^-alkenyl-halogenid eller C-^-Cg-alkylhalogenid, eventuelt substituert som angitt ovenfor, i nærvær av en base slik som Ua^ CO^, K2C03'NaH'NaNH2i et°PPløsningsmiddel slik som dimetylformamid, dimetylacetamid, dioksan, tetrahydrofuran og deres blandinger, ved en temperatur som varierer mellom romtemperatur og ca. 100°C.
En forbindelse med formel I hvoriR^er hydrogen kan omdannes til en forbindelse med formel I hvor R, er formyl ved oppvarming med maursyre og ved en temperatur som varierer mellom ca. 50°C og ca. 100°C.
En forbindelse med formel I hvori R^er hydrogen, kan omdannes til en forbindelse med formel I der R^er C2~Cg-alkanoyl, eventuelt substituert som angitt ovenfor, f.eks. ved omsetning med et egnet C2~Cg-alkanoylhalogenid eller anhydrid i nærvær av en base slik som pyridin eller trietylamin eller i et oppløsningsmiddel slik som dimetylformamid, dioksan, tetrahydrofuran eller uten et oppløsnignsmiddel, ved en temperatur som varierer mellom ca. 50°C og ca. 150°C.
En forbindelse med formel I hvori m er 0 og R, er formyl eller C2~Cg-alkanoyl, eventuelt substituert som angitt ovenfor, kan omdannes til en forbindelse med formel I hvori m er 0 og R^er hydrogen, f.eks. ved sur hydrolyse, f.eks.
ved bruk av saltsyre, hydrobromsyre eller hydrojodsyre i vandig oppløsning i nærvær hvis nødvendig av et organisk medoppløsningsmiddel slik som dioksan eller eddiksyre, ved å arbeide ved en temperatur som varierer mellom romtemperatur og tilbakeløpstemperaturen eller ved basisk hydrolyse, f.eks. ved bruk av natriumhydroksyd eller kaliumhydroksyd i vandig oppløsning i nærvær av, hvis nødvendig, et organisk oppløsningsmiddel slik som dioksan eller en laverealkyl-alkohol, ved å arbeide ved en temperatur som varierer mellom romtemperatur og tilbakeløpstemperatur.
En forbindelse med formel I hvori R^ er en gruppe CH^ Z,
der Z er som angitt ovenfor, kan omdannes til en forbindelse med formel I der R er en gruppe -CH„N 7, hvori R7og Rp er som angitt ovenfor, ved omsetning med en forbindelse med formel HN 7, hvori R_. og RQer som angitt ovenfor, i et
8lo
inert organisk oppløsningsmiddel slik som dioksan, dimetylformamid, dimetylacetamid ved en temperaturer som varierer mellom romtemperatur og tilbakeløpstemperatur, fortrinnsvis mellom romtemperatur og ca. 100°C.
Også den eventuelle saltdannelse av en forbindelse med formel I så vel som omdanning av et salt til den frie forbindelse og separering av en blanding av isomerer til de enkelte isomerer, kan gjennomføres ved konvensjonelle metoder.
F.eks. kan separering av en blanding av optiske isomerer i de individuelle isomerer gjennomføres ved saltdannelse med en optisk aktiv base og etterfølgende fraksjonert krystallisering.
Således kan separeringen av en blanding av geometriske isomerer f.eks. gjennomføres ved fraksjonert krystallisering.
Forbindelsene med formel II, hvoriR^er hydrogen, kan f.eks. fremstilles ved å redusere en forbindelse med formel VIII n, / R^, R^og Rg er som angitt ovenfor, med et egnet reduksjonsmiddel slik som tinn(II)klorid eller natriumborhydrid. Reduksjonen av en forbindelse med formel VIII
med tinn(II)klorid kan gjennomføres f.eks. i konsentrert saltsyre ved bruk, hvis nødvendig, av et organisk medopp-løsningsmiddel slik som eddiksyre, dioksan eller tetrahydrofuran ved en temperatur som varierer mellom romtemperatur og tilbakeløpstemperaturen, fortrinnsvis mellom romtemperatur og ca. 60°C. Reduksjon av en forbindelse med formel VIII med natriumborhydrid kan f.eks. gjennomføres i C-^-C^-alifatiske alkoholer, fortrinnsvis isopropylalkohol, tetrahydrofuran, dimetylformamid, dimetylacetamid, vann og blandinger derav, ved å arbeide ved en temperatur som varierer mellom romtemperatur og ca. 60°C.
Forbindelsene med formel II, hvori R^er formyl eller gruppen C^-Cg-alkanoyl, eventuelt substituert som angitt ovenfor, kan f.eks. fremstilles ved omsetning av en forbindelse med formel II, hvoriR^er hydrogen, henholdsvis med maursyre ved en temperatur mellom ca. 50°C og ca. 100°C eller med et egnet C2-Cg-alkanoylhalogenid eller anhydrid i nærvær av en base slik som pyridin eller trietylamin, enten i et oppløs-ningsmiddel slik som dimetylformamid, dioksan, tetrahydrofuran eller uten et oppløsningsmiddel, ved en temperatur som varierer mellom ca. 50°C og ca. 150°C.
Forbindelser med formel II hvori R^er en gruppe C^-C^- alkenyl ellerC^-C^-alkyl, eventuelt substituert som angitt ovenfor, kan f.eks. fremstilles ved omsetning av en forbindelse med formel II, hvori R, er formyl eller C~-C0-alkanoyl,
l2. o eventuelt substituert som angitt ovenfor, med et egnet C^-C^-alkenylhalogenid eller C,-C ,-alkylhalogenid, i nærvær av en base slik som Na2CC>3, f^CO^ , NaH, NaNH2i et oppløsnings-middel slik som dimetylformamid, dimetylacetamid, dioksan, tetrahydrofuran og deres blandinger, ved en temperatur som varierer mellom romtemperatur og ca. 100°C, og deretter hydrolysere formyl- eller C-j-Cg-alkanoyldelen, f.eks. ved behandling med en mineralsyre slik som saltsyre, hydrobromsyre eller hydrojodsyre i vandige media ved en temperatur som varierer mellom romtemperatur og ca. 100°C.
Forbindelsene med formel VI kan f.eks. fremstilles ved omsetning av en forbindelse med formel IX
hvori
n, R^og R^ er som angitt ovenfor, med en forbindelse med formel III, IV eller V, for å oppnå henholdsvis forbindelser med formel VI der m er 1; eller m er 1, R2er karboksy og X er som angitt ovenfor, bortsett fra en enkeltbinding; eller m er 0.
Reaksjonen mellom en forbindelse med formel IX og en forbindelse med formel III, IV eller V kan gjennomføres f.eks. ved å benytte de samme eksperimentforsøk som beskrevet ovenfor, for omsetning av en forbindelse med formel II og en forbindelse med formel III, IV eller V.
Alternativt kan forbindelsene med formel VI, der R-^er C^-C^-alkenyl eller C^-Cg-alkyl, eventuelt substituert som angitt ovenfor, f.eks. fremstilles ved osmetning av en for bindelse med formel VI, der er hydrogen med et egnet -C^-alkenylhalogenid eller C^-Cg-alkylhalogenid i nærvær av en base slik som Na^CO^, K^CO^ , NaH, NaNH^ i et oppløs-ningsmiddel slik som dimetylformamid, dioksan, tetrahydrofuran og deres blandinger, ved en temperatur som varierer mellom romtemperatur og ca. 100°C. Forbindelsene med formel VIII kan f.eks. fremstilles ved å omsette en forbindelse med formel X
hvori
n og R^er som angitt ovenfor, med et aldehyd med formel VII, ved bruk av de samme eksperimentbetingelser som beskrevet ovenfor for reaksjonen mellom en forbindelse med formel VI og et aldehyd med formel VII.
Forbindelsene med formel IX, hvori R-^er hydrogen, kan f.eks. fremstilles ved behandling av en forbindelse med formel X med et reduksjonsmiddel slik som tinn(II)klorid eller natriumborhydrid som beskrevet ovenfor for reduksjon av forbindelsene med formel VIII.
Forbindelsene med formel IX hvori R-^ er forskjellig fra hydrogen kan f.eks. fremstilles ut fra forbindelser med formel IX hvori R^er hydrogen ved bruk av de samme kjemiske prosesser som er beskrevet ovenfor for fremstilling av forbindelser med formel II, hvori R^er forskjellig fra hydrogen .
Forbindelsene med formel X kan fremstilles ved kjente metoder, f.eks. i henhold til de metoder som er beskrevet i den publiserte GB søknad 2103207A.
Forbindelsene med formlene III, IV, V og VII er kjente forbindelser og kan fremstilles ved konvensjonelle metoder;
i enkelte tilfeller er de kommersielt tilgjengelige produk-ter .
Forbindelsene med formel I har antiallergisk virkning og er derfor brukbare ved forhindring og behandling av alle på-virkninger av allergisk opprinnelse, f.eks. bronkial astma, allergisk rhinitt, høyfeber, urticaria og dermatose. Den antiallergiske virkning for forbindelsene ifølge oppfinnelsen vises f.eks. ved det faktum at de er aktive i de følgende biolotiske prøver:
in vitro
1) prøve på A 23187 indusertSRS-produksjon fra rotte peritoneale celler i henhold til M.K. Bach og J.R. Brashler
("J. Immunol.", 113, 2040, 1974); 2) prøve på antigen indusert SRS-produksjon fra marsvin hakket lunge, i henhold til W.E. Brocklehurst ("J. Physi-ol.", 151, 416, 1960) ;
in vivo
3) prøve på IgG-mediert passiv peritoneal anafylakse hos rotter i henhold til H.C. Morse, K.J. Bloch og K.F. Austen
("Journal Immunology", 101, 658, (1968); og
4) prøve på IgE-mediert passiv kutan anafylakse (PCA) hos rotter, i henhold til A.M.J.N. Blair ("Immunology", 16, 749, 1969) .
Resultattene av disse biologiske prøver viser at forbindelsene ifølge oppfinnelsen er aktive, f.eks. som inhibitorer av immunologisk frigivelse av allergiske mediatorer, f.eks. histamin, fra dyrkingscellene og som inhibitorer for fremstilling og I eller frigivelse av anafylaktiske mediatorer, slik som "langsomtreagerende stoffer" (RSR) i den peritoneale og pulmonære system, indusert av utfordring med en ionofor elelr med et antigen.
En viktig egenskap for forbindelsene ifølge oppfinnelsen
er at de er aktive som antiallergiske stoffer også når de inngis oralt.
For foretrukket eksempel på en forbindelse med antiallergisk aktivitet skal den følgende nevnes: N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre.
I lys av den høye terapeutiske indeks kan forbindelsene ifølge oppfinnelsen på sikker måte benyttes i medisinen.
F.eks. er den omtrentlige akutte giftighet, LD^-g, for for-bindelsen : N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre,
i mus, bestemt ved enkel inngivelse med økende doser og målt den syvende dag etter behandling per os over 800 mg/kg.
Analoge giftighetsdata er funnet for andre forbindelser ifølge oppfinnelsen.
Forbindelsene ifølge oppfinnelsen kan inngis til mennesker
på vanlig måte, f.eks. oralt elle parenteralt ved daglige doser fortrinnsvis fra ca. 0,5 til ca. 15 mg/kg, eller ved inhalering, fortrinnsvis ved en daglig dose fra ca. 0,5 til ca. 1500 mg, fortrinsnvis 0,5 til 25 mg, eller ved topisk anvendelse, (f.eks. for behandling av ureticaria og dermatose), f.eks. ved hjelp av en krem inneholdende fra 0,5 til 5 mg og fortrinnsvis 1-2 mg, av den aktive bestanddel pr.
100 mg krem.
Arten av de farmasøytiske preparater inneholdende forbindelsene ifølge oppfinnelsen i forbindelse med farmasøytisk akseptable bærere eller fortynningsmidler ville selvfølgelig av-henge av den ønskede inngivelsesvei. Preparatene kan for-muleres på konvensjonell måte med de vanlige bestanddeler. F.eks. kan forbindelsene ifølge oppfinnelsen gis i form av vandige eller oljeaktige oppløsninger eller suspensjoner, aerosoler, så vel som pulvere, tabletter, piller, gelatinkapsler, siruper, dråper, suppositorier eller kremer, eller losjoner for topisk bruk.
For oral inngivelse er således de farmasøytiske preparater som inneholder forbindelsene ifølge oppfinnelsen fortrinnsvis tabletter, piller eller gelatinkapsler som inneholder den aktive substans sammen med fortynningsmidler slik som laktose, dekstrose, sukrose, mannitol, sorbitol, cellulose; smøremidler som f.eks. silisiumdioksyd, talkum, stearinsyre, magnesium eller kalsiumstearat, og/eller polyetylenglykoler; eller de kan også inneholde bindemidler slik som stivelser, gelatin, metylcellulose, karboksymetylcellulose, gummi-ara-bikum, tragakantgummi, polycinylpyrrolidon; disaggregerings-midler slik som stivelser, alginsyre, alginater, natrium-stivelsesglykolat; efferveseringsblandinger; fargestoffer; søtnere; fuktemidler slik som lecitin, polysorbater, lauryl-sulfater; og generelt ikke-toksiske og farmakologisk inaktive stoffer som benyttes i farmasøytiske formuleringer.
Nevnte farmasøytiske preparater kan fremstilles på kjent måte, f.eks. ved hjelp av blanding, granulering, tablettering, sukker-belegging eller film-belegging.
For behandling av allergisk astma kan forbindelsene ifølge oppfinnelsen også inngis ved inhalering. For slik anvendelse kan egnede preparater omfatte en suspensjon eller oppløsning av den aktive bestanddel, fortrinnsvis i form av et salt, slik som natriumsaltet eller saltet med trietanolamin eller med tris-(hydroksymetyl)-aminometan, i vann, for inngivelse ved hjelp av en konensjonell forstøver.
Alternativt kan preparaene omfatte en suspensjon eller en opp-løsning av den aktive bestanddel i et konvensjonelt flytende-gjort drivmiddel slik som diklordifluormetan eller diklor-tetrafluoretan for inngivelse fra en beholder under trykk,
f.eks. en aerosoldispenser.
Når medikamentet ikke er oppløselig i drivmidlet, kan det være nødvendig å tilsette et medoppløsningsmiddel slik som etanol, dipropylenglykol, isopropylmyristat og/eller overflateaktive midler til preparatet, for å suspendere medikamentet i drivmiddelmediet og slike overflateaktive midler kan være et hvilket som helst av de som vanligvis benyttes for dette formål slik som ikke-ioniske overflateaktive midler, f.eks. lecitin.
Forbindelsene ifølge oppfinnelsen kan også inngis i form av pulvere ved hjelp av en egnet insufflatorinnretning og i dette tilfellet kan pulverne med fin partikkelstørrelse og med den aktive bestanddel blandes med et fortynningsmiddel slik som laktose.
Videre kan forbindelsene ifølge oppfinnelsen også inngis ved intradermal eller intravenøs injeksjon på konvensjonell måte.
I tillegg til den indre inngivelse, kan forbindelsene ifølge oppfinnelsen finne anvendelse i preparater for topisk anvendelse, f.eks. som kremer, lotioner eller pastaer for bruk i dermatologiske behandlinger.
For disse preparater kan den aktive bestanddel blandes med konvensjonelle oljelignende eller emulgerende strekkmidler. D'e følgende eksempler skal illustrere, men ikke begrense oppfinnelsen.
Eksempel 1
6-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,1-b) kinazolin-9-on, smeltepunkt 268-270°C (3,1 g) ble omsatt med etyloksalylklorid (3,2 g) i dimetylacetamid (30 ml) i nærvær av pyridin (3 ml) ved romtemperatur i 16 timer.
Reaksjonsblandingen ble fortynnet med isvann og presipitatet ble filtrert og vasket med vann: krystallisering fra dimetylformamid ga N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,1-b ]kinazolin-6-yl)-amino-oksoeddiksyre, etylester, sm.p. 248-250°C (3 g), som ble fortynnet i dimetylformamid (150 ml) og behandlet med 5% vandig NaOH (150 ml) ved romtemperatur i 5 timer.
Presipitatet, N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,1-b ]kinazolin-6-yl)-amino-oksoeddiksyre, natriumsalt, sm.p. >300°C, ble filtrert og vasket med vann, og deretter ble det oppløst i maursyre og oppløsningen ble fortynnet med vann, hvorved man oppnådde et presipitat som ble filtrert og vasket med vann til nøytral tilstand.Krystalli-sering fra maursyre ga 1,4 g N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b ]kinazolin-6-yl)-amino-oksoeddiksyre, sm.p. 220-225°C,
NMR (DMSO d6) 6 ppm: 3,22 (m) (2H, C-2-protoner), 4,11 (m)
(2H, C-l-protoner), 7,25-7,80 (m) (6H, -CH= og fenylprotoner), 7,75 (dd) (1H, C-7-proton), 8,02 (d) (1H, C-8-proton), 8,20 (d) (1H, C-5-proton), 11,0 (bs) (1H, -NH-C0-).
Ved å gå frem på analog måte ble følgende alkylestere og syrer fremstilt: N-(6-benzyliden-ll-okso-6,7,8,9-tetrahydro-llH-pyrido[2,1-b]-kinazolin-3-yl)-amino-oksoeddiksyre, etylester, sm.p. 193-195°C; N-(6-benzyliden-ll-okso-6,7,8,9-tetrahydro-llH-pyrido[2,1-b]-kinazolin-3-yl)-amino-oksoeddiksyre, sm.p. 350°C dek.,
NMR (CF3COOD + DMSO d6)6ppm: 2,14 (m) (2H, C-8-protoner), 3,05 (m) (2H, C-7 protoner), 4,16 (m) (2H, C-9-protoner), 7,58 (m) (3H) og 7,74 (m) (2H) og 8,05 (m) (2H) (-CH=,.fenylprotoner og C-2 proton)/8,33 (d) (1H, C-l-proton), 8,78 (bs)
(1H, C-4-proton);
N-(3-benzyliden-1-mety1-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl)-amino-oksoeddiksyre, etylester,
sm.p. 232-235°C;
N-(3-benzyliden-1-mety1-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-amino-oksoeddiksyre, sm.p. 211-225°C; N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-7-yl)-amino-oksoeddiksyre, etylester, sm.p. 270-272°C og N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-7-yl)-amino-oksoeddiksyre, sm.p. 239-242°C,
NMR (DMSO d6) 6 ppm: 3,24 (m) (2H, C-2-protoner), 4,17 (t)
(2H, C-l protoner), 7,33-7,78 (m) (7H, -CH=, C-5-proton og fenylprotoner), 8,10 (dd), (1H, C-6-proton), 8,65 (d)
(1H, C-8-proton), 10,99 (s) (1H, -NH-CO-).
Eksempel 2
6-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-9-on (2,5 g) ble omsatt med 3-karbometoksypropionyl-klorid (1,95 g) i dimetylacetamid (110 ml) i nærvær av pyridin (2ml) ved romtemperatur i 18 timer. Reaksjonsblandingen ble deretter fortynnet med isvann og bunnfallet filtrert og vasket med vann og man oppnådde 3-[N-(3-benzyli-den-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-aminokarbonyl]-propansyremetylester, sm.p. 288-291°C (3,3 g) som ble oppløst i dimetylformamid (120 ml) og behandlet med 5 %-ig vandig NaOH (32,5 ml) ved romtemperatur i 3 timer. Presipitatet, 3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolof 2,1-b]kinazolin-6-yl)-aminokarbonyl]-propansyre, natriumsalt, sm.p. >300°C ble filtrert og vasket med vann,
og ble deretter oppløst i maursyre og oppløsningen ble fortynnet med vann og man oppnådde et presipitat som ble filtrert og vasket med vann til nøytral tilstand, hvorved man oppnådde 2,07 g 3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,1-b]kinazolin-6-yl)-aminokarbonyl]-propansyre,
sm.p. 250-255°C dek.,
NMR (DMSO d6) 6 ppm; 2,62 (bs) (4H, -COCH2CH2-C00H), 3,18
(m) (2H, C-2-protoner), 4,08 (t) (2H, C-l-protoner), 7,30-7,70 (m) (7H, C-5- og C-7-protoner og fenylprotoner), 7,98 (d) (1H, C-8-proton), 8,07 (t) (1H, -CH=), 10,31 (ds) (1H,
-NHC0-).
Ved å gå frem på analog måte fremstilte man følgende alkylestere og syrer: N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl-eddiksyre, etylester, sm.p. 227-229°C; N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl-eddiksyre, sm.p. 307-310°C; (E)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, sm.p. 315-320°C: (E)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, etylester, sm.p. 298-300°C; 3- [N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, metylester, sm.p. 284-287°C; 3 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, sm.p. 384-387°C; 4- [N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, metylester, sm.p. 280-285°C; 4 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, sm.p. 310-315°C; 2- [N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-4,5-diklor-benzosyre, metylester: 3- benzyliden-6-N-etoksykarbonyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, sm.p. 285-288°C; 3-benzyliden-6-N-metoksykarbonyl-amino-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 2-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-4,5-diklor-benzosyre; 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-propansyre, etylester; 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-propansyre; 2-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-2-metyl-propansyre, etylester; 2 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-metyl-propansyre; 2-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]-kinazolin-6-yl) -aminokarbonyl ] -smørsyre ,; etylester ; 2-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-smørsyre; 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-2-etyl-smørsyre, etylester; 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2-etyl-smørsyre; 2 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2-fenyl-eddiksyre, etylester; og 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-fenyl-eddiksyre. Eksempel 3 6-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on (2 g) ble omsatt med ftalsyreanhydrid (4,6 g) i tetrahydrofuran (150 ml) under omrøring ved tilbakeløps-temperaturen i 14 timer. Etter avkjøling ble presipitatet filtrert og vasket med tetrahydrofuran og deretter med vann og man oppnådde 1,6 g 2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl)-aminokarbonyl]-benzosyre, sm.p. 302-308°C. NMR (CDCl3-CF3COOD) S ppm: 3,61 (bt) (2H, C-2-protoner), 4,65 (t) (2H, C-l-protoner), 7,4-8,0 (m) (7H, fenyl og C-4- og C-5-benzoylprotoner), 8,0-8,5 (m) (6H; -CH=, C-5- og C-7- og C-8-protoner, C-3- og C-6-benzoylprotoner).
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: cis-2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-l-cykloheks-4-en-karboksylsyre, sm.p. 245-248°C;
2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-cykloheks-l-en-karboksylsyre;
cis-2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrroio-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-cykloheksan-kårbok-sylsyre; og
2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-3,4,5,6-tetraklor-benzosyre.
Eksempel 4
6-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-9-on (3 g) ble omsatt med maleinsyreanhydrid (4,55 g)
i tetrahydrofuran (220 ml) under omrøring ved tilbakeløps-temperatur i 14 timer. Etter avkjøling ble bunnfallet filtrert av og vasket med tetrahydrofuran og deretter med vann: krystallisering fra dimetylformamid ga 2,8 g (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-2-propensyre, sm.p. 210-230°C.
NMR (CDC13 + CF3COOD) 6 ppm: 3,53 (m) (2H, C-2-protoner), 4,57 (m) (2H, C-l-protoner) , 6,51 (d) (1H, ct-propenoylproton), 6,78 (d) (1H, g-propenoylproton), 7,58 (bred topp)
(5H, fenylprotoner), 8,00-8,40 (m) (4H, -CH= og C-5-, C-7-og C-8-protoner); J„ „ n = 12,5 Hz.
ria n B
Ved å gå frem på tilsvarende måte ble følgende forbindelser fremstilt: (Z)-3 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2,3-dimetyl-2-propensyre; 4 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-smørsyre;
5- [N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-pentansyre; og 4-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-3,3-dimetyl-smørsyre.
Eksempel 5
6- amino-3-benzyliden-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kina-
zolin-9-on (2 g) ble omsatt med 2,3-diklor-maleinsyreanhydrid (3,46 g) i tetrahydrofuran (130 ml) under omrøring ved tilbakeløpstemperaturen i 3 timer. Etter avkjøling ble oppløsningen fordampet i vakuum til tørr tilstand: resten ble suspendert i varm etylacetat og filtrert. Krystallisering fra Cf^C^-etylacetat ga 1 g (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazo-1in-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre, sm.p. 160-165°C (dek.),
NMR (DMSO d6) 6ppm: 3,23 (m) (2p, C-2-protoner), 4,14 (m)
(2p, C-l-protoner), 7,35-7,80 (m) (7H, C-5- og C-7-protoner og fenylprotoner), 8,07 (d) (1H, C-8-proton), 8,08 (bs)
(1H, -CH=), 11,15 (s) (1H, CONH).
Eksempel 6
Ved å gå frem i henhold til eksempel 1 og ved å benytte egnede 6-amino-3-substituert benzyliden-1,2,3,9-tetrahydro-pyrrolof2,l-b]kinazolin-9-oner, ble følgende forbindelser fremstilt: N-[3-(2-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl ]-amino-oksoeddiksyre, etylester, sm.p. 248-251°C: N-[3-(3-metyl-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 230-233°C;
N-[3 -(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 288-290°C;
N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 260-262°C;
N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 242-244°C;
N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p.. 265-268°C;
N-[3 -(4-fluor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 240-243°C;
N-[3-(2-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 230-233°C; N-[3-(2,3-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 170-175°C; N-[3-(3,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre ; etylester, sm.p. 273-275°C; N-[3-(4-nitro-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3 -(4-amino-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3-(3-trifluormetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo- [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 245-250°C; N-[3-(3,4-metylendioksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 275-280°C; N-[3 -(2,5-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 257-259°C; N-[3-(2,4-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2 ,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3-(2-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b ]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 212-214°C;
N-[3-(3-etoksy-benzylidén)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 223-226°C;
N-[3 -(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[ 2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester,
sm.p. 253-256°C;
N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 252-255°C;
N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 244-247°C; N-[3-(2-metoksy-3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 212-216°C; N-[3 -(2,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 264-267°C; N-[3-(3,5-dimetoksy-benzyliden)-9-okso-l,2,3,8-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3-(2,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3 -(3,4,5-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-okso-eddiksyre, etylester, sm.p. 285-288°C; N-[3-(2,3,4-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-okso-eddiksyre, etylester; N-[3-(2-etoksy-3-metoksy-benzyliden)-9-okso-1,2,3,9-tetra-hydro-pyrrolo [2,1-b]kinazolin-6-yl]-amino-okso-eddiksyre, etylester; N-[3 -(2,3-dietoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; sm.p. 174-177°C; N-[3-(2-propoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3-(3-propoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3 -(4-propoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3 -(2-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3-(3-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolof 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3 -(4-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3-(3,4-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester ; N-[3-(2,4-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; sm.p. 244-246°C; N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester, sm.p. 234-237°C; N-[3 -(4-N,N-dimetylamino-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, etylester; N-[3 -(2-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 235-240°C, dek. ; N-[3 -(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 232-235°C; N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 253-256°C; N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2 , 1-b ] kinazolin-6-yl ] -amino-oksoeddiksyre , sm.p. 246-248°C; N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2 , 1-b ] kinazolin-6-yl ] -amino-oksoeddiksyre , sm.p. 195-205°C dek.; N-[3 -(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 236-240°C;
N-[3-(4-fluor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 246-248°C; N-[3-(2-klor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 300-310°C dek. ; N-[3 -(2,3-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 253-255°C;
N-[3-(3,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 250-260°C dek.;
N-[3-(2-metoksy-3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]amino-oksoeddiksyre,
sm.p. 228-230°C dek.;
N-[3-(2,5-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]amino-oksoeddiksyre,
sm.p. 347-349°C;
N-[3 -(2,4-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 215-220°C;
N-[3 -(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 238-240°C; N-[3 -(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2 ,1-b ] kinazolin-6-yl ]-amino-oksoeddiksyre, sm.p. 240-245°C dek.; N-[3 -(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 226-229°C; N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 236-240°C; N-[3 -(2,3,4-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2-etoksy-3-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2,3-dietoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 220-222°C; N-[3 -(2-propoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3-propoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(4-propoksy-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3,4-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(2,4-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 205-215°C dek.;
N-[3 -(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 222-226°C;
N-[3 -(3,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(2-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(4-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3 -(3,4-metylendioksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 225-229°C; N-[3-(4-nitro-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo^,1-b ]kinazolin-6 -yl] -amino-oksoeddiksyre; N-[3-(4-amino-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre; N-[3-(3-trifluormetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 250-265°C dek.; N-[3-(2,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 238-243°C dek.;
N-[3 -(3,4,5-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 221-225°C;
N-[3 -(4-metoksykarbonyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre, sm.p. 282-285°C; N-[3-(4-karboksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-amino-oksoeddiksyre,
sm.p. 240-250°C dek.; og
N-[3 -(4-N,N-dimetylamino-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-amino-oksoeddiksyre.
Eksempel 7
Ved å gå frem i henhold til eksempel.2 og ved å bruke egnede 6-amino-3-substituert benzyliden-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-9-oner fremstilles følgende forbindelser; N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3 -(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3 -(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo^,1-b ]kinazolin-6-yl] -aminokarbonyl-eddiksyre; N-[3 -(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3 -(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2 ,1-b ]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3-(2,3-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolof 2,1-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; N-[3—(2,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro- pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl-eddiksyre; 3 -{N-[3 -(3-metyl-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; 3-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; 3 -{N-[3 -(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; 3-{N-[3 -(2-metoksy-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; 3 -{N-[3- (3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 3-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre ; 3-{N-[3-(4-klor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; 3-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-propansyre; (E)-3-{N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-2-propensyre; (E)-3-{N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre ; (E)-3-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(4-klor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (E)-3-{N-[ 3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(E)-3-{N-[3-(2-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl) -2-propensyre; 2-{N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolof 2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-propansyre; 2-{N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl)-2-metyl-propansyre; 2-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl)-2-metyl-propansyre; 2-{N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl)-2-metyl-propansyre; 2 -{N-[3 -(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl)-2-metyl-propansyre; 2-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl)-2-metyl-propansyre; 2-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-metyl-propansyre;
2-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-metyl-propansyre; og 2 -{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-metyl-propansyre.
Eksempel 8
Ved å gå frem i henholde til eksempel 3 og ved å benytte egnede 6-amino-substituert benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-oner, ble følgende forbindelser fremstilt: 2-{N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-(N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; 2-{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-benzosyre; cis-2-{N-[3-(3-mety1-benzyliden-9-okso-1,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; cis-2-{N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; cis-2-{N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; cis-2-{N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; cis-2-{N-[3-(3-metoksy-benzyliden)-9-okso-1,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; cis-2-(N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-kårboksylsyre; cis-2-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre; og cis-2-{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-1-cykloheks-4-en-karboksylsyre.
Eksempel 9
Ved å gå frem i henhold til eksemplene 4 og 5 og ved å benytte egnede 6-amino-3-substituert-benzyliden-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-oner fremstilles følgende forbindelser: (Z)-3-{N-[3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(Z)-3-{N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl>-2 - propensyre;
(Z)-3-(N-[3-(4-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydropyrrolof 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2 - propensyre;
(Z)-3-{N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl) - 2-propensyre;
(Z)-3-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(Z)-3-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-2-propensyre;
(Z)-3-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(Z)-2-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre ;
(Z)-3-{N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre; (Z)-3-{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(Z)-3-{N- 3-(2-klor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2-propensyre;
(Z)-3-{N- 3-(2-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-(N- 3-(3-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3 -{N-[3 -(4-metyl-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3 - diklor-2-propensyre;
(Z)-3-{N-[3-(3-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-metoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-fluor-benzyliden)-9-okso-1,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonylJ-2,3 - diklor-2-propensyre;
(Z)-3-{N-[3-(2-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo [_2 ,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-
2-propensyre;
(Z)-3-{N-[3-(2-etoksy-3-metoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolof 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,3-dietoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-klor-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3,4-metylendioksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2-etoksy-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-etoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,6-diklor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-(N-[3 -(3,4-diklor-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3 - diklor-2-propensyre;
(Z)-3-{N- 3-(4-nitro-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-amino-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2-propoksy-benzyliden)-9-okso-l,2,3,9-tetra-
2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3,5-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,5-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,4-dimetyl-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3-trifluormety1-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre; og
(Z)-3-[N-(3-benzyliden-l-metyl-9-okso-l,2,3,9-tetrahydro-pyrrolo [2 ,l-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2- propensyre.
Eksempel 10
3- [N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, metylester (0,85 g) oppløst i dimetylformamid (40 ml) ble tilsatt til en suspensjon av 50 %-ig NAh (0,18 g) i dimetylformamid (5 ml) og blandingen ble omrørt ved romtemperatur i en time og deretter omsatt med metyljodid (0,54 g) ved romtemperatur i 17 timer. Reaksjonsblandingen ble fortynnet med isvann og deretter surgjort med eddiksyre: bunnfallet ble filterert og renset over en flashkolonne ved bruk av kloroform-etylacetat 3:1 som elueringsmiddel. En ytterligere rensing fra isopropyleter ga 3-[N-metyl-N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl)-aminokarbonyl]-benzosyre, metylester, sm.p. 200-202°C (0,42 g), som ble
hydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3 - diklor-2-propensyre;
(Z)-3-(N-[3-(3-propoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [ 2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-propoksy-benzyliden)-9-okso-l,2,3,9-tetra-hydro-pyrrolo [2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3 - diklor-2-propensyre;
(Z)-3-(N-[3-(2-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-(N-[3-(3-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(4-isopropoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3 -(2,4-diklor-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2-metoksy-3-etoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3-N,N-dimetylamino-benzyliden)-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-amino-karbonyl }-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,3,4-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3,4,5-trimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(2,3-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl)-2,3-diklor-2-propensyre;
(Z)-3-{N-[3-(3,4-dimetoksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl]-aminokarbonyl}-
oppløst i dimetylformamid (20 ml) og behandlet med 5 %-ig vandig NaOH (3,6 ml) ved romtemperatur i 2 timer. Bunnfallet, 3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetra-hydro-pyrrolo[2,l-b]kinazolin-6-yl)-aminokarbonyl]-benzosyre, natrium, sm.p. >300°C ble filtrert og deretter opp-løst i maursyre; oppløsningen ble fortynnet med vann og man oppnådde et presipitat som ble filtrert og vasket med vann til nøytral tilstand.Krystallisering fra diklormetan-metanol ga 0,2 g 3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-amino-karbonyl ] -benzosyre , sm.p. 302-304°C,
NMR (CDC13) 6 ppm: 3,38 (m) (2H, C-2-protoner), 3,61 (s)
(3H, CH3), 4,32 (t) (2H, C-l-protoner), 7,14 (dd) (1H, C-7-proton) , 7,3.2 (t) (1H, C-5-benzoylproton) , 7,35-7,85
(m) (7H, C-4- og C-6-benzoylprotoner og fenylprotoner),
7,88 (bs) (1H, -CH=), 8,00 (bd) (1H, C-5-proton), 8,13 (d)
(1H, C-8-proton), 8,15 (bs) (1H, C-2-benzoylproton).
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre;
NMR (CDC13) 6 ppm: 3,30 (M) (2H, C-2-protoner), 3,45 (S)
(3H, CH3), 4,28 (T) (2H, C-l-protoner), 7,2-7,6 (M) (7?? C-5-, C-7- og fenylprotoner), 7,85 (T) (1H, =CH-), 8,28 (D)
(1H, C-8-proton).
N-etyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre;
N-benzyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre;
N-metyl-N-(6-benzyliden-ll-okso-6,7,8,9-tetrahydro-llH-pyrido[2,1-b]kinazolin-3-yl)-amino-oksoeddiksyre; N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl-eddiksyre; 3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-propansyre; (Z)-3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro- pyrrolo[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre; N-diklormetyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre; (Z)-3-[N-diklormetyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre;
(Z)-3-[N-etyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [ 2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propen-
syre ; (E)-3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre; 2 -[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-aminokarbonyl]-propansyre;
og
(Z)-3-[N-metyl-N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre.
Eksempel 11
2-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre (2 g) oppløst i varm dimetylformamid (30 ml) ble behandlet med NaHCO^
(0,4 g) oppløst i litt vann i 30 minutter ved romtemperatur. Etter fortynning med isvann ble bunnfallet filtrert av og vasket med vann, og man oppnådde 1,8 g 2 -[N-(3-benzy-liden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-aminokarbonyl]-benzosyre, natriumsalt, sm.p. >300°C.
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: cis-2-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-l-cykloheks-4-en-karboksylsyre, natriumsalt, sm.p. >300°C;
(Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, natriumsalt, sm.p. >300°C.
Eksempel 12
(Z)-3-(N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre (1,22 g) ble oppvarmet i vannfri metanol (19 0 ml) inneholdende bortrifluorideterat (1,58 ml) ved tilbakeløpstemperatur 1 8 timer. Reaksjonsblandingen ble konsentrert til et lite volum i vakuum og presipitatet ble filtrert og vasket med vann til nøytral tilstand, hvorved man oppnådde 1,1 g av (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, metylester, sm.p. 233-235°C.
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, etylester; 3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-propansyre, etylester; 2 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-aminokarbonyl]-benzosyre, etylester; og (Z)-3-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre, etylester.
Eksempel 13
6-amino-3-benzy1iden-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on (2 g) ble omsatt med 3-piperidino-propionyl-klorid, hydroklorid (3,66 g) i dimetylacetamid (120 ml) i nærvær av pyridin (2,8 ml) ved romtemperatur i 18 timer. Reaksjonsblandingen ble deretter fortynnet med isopropyleter (1 liter) og det klebrige presipitat ble oppløst i vann.
Etter nøytralisering med Na2HP04 ble den vandige oppløsning ekstrahert med kloroform: fordamping av den organiske fase i vakuum til tørr tilstand og krystallisering fra kloroform- metanol ga 1,9 g 3-benzyliden-6-N-(3-piperidino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on,
sm.p. 230-234°C,
NMR (CDC13+ CF3COOD) <S ppm: 1,68 (m) (6H, C-3-, C-4- og C-5-pieridinylprotoner), 2,62 (m) (8H, C-2- og C-6-piperi-dinylprotoner og -COCH2CH2N<) , 3,72 (tt) (2K, C-2-protoner), 4.22 (t) (C-l-protoner), 7,28-7,62 (m) (5H, fenylprotoner), 7,62 (dd) (1H, C-7-proton), 7,80 (t) (1H, -CH=), 7,90 (d)
(1H, C-5-proton), 8,18 (1H, C-8-proton).
Eksempel 14
6-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-9-on (2,3 g) ble omsatt med kloracetylklorid (1,35 g) i dimetylacetamid (100 ml) i nærvær av pyridin (1,9 ml) ved romtemperatur i 3 timer.
Reaksjonsblandingen ble fortynnet med isvann og bunnfallet ble filtrert og vasket med vann og man oppnådde 3-benzyliden-6-N-kloracetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 281-284°C dek. ('2,4 g) , som ble omsatt med morfolin (0,63 g) i dimetylacetamid (90 ml) i nærvær av vannfri kaliumkarbonat (1 g) under omrøring ved 60°C i 4 timer. Etter avkjøling ble bunnfallet filtrert av og vasket med vann: krystallisering fra aceton-etanol ga 1,4 g 3-benzyliden-6-N-morfolinacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, sm.p. 223-225°C,
NMR (CDC13)6ppm: 2,70 (m) (4H, C-3- og C-5-morfolinylpro-toner), 3,23 (s) (2H, -CO-CH2~N<) , 3,28 (dt) (2H, C-2-protoner), 3,82 (m) (4H, C-2- og C-6-morfolinylprotoner),
4,25 (t) (2H, C-l-protoner), 7,33-7,70 (m) (6H, C-7-proton og fenylprotoner), 7,70-7,92 (m) (2H, =CH- og C-5-proton), 8.23 (d) (1H, C-8-proton).
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: 3-benzyliden-6-N-piperidinoacetyl-amino-1,2,3,9-tetra-hydro-pyrrolo [ 2 ,l-b]kinazolin-9.—on;
3-benzyliden-6-N-[ (4-metyl-l-piperaz inyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
sm.p. 252-254°C;
3-benzyliden-6-N-[(lpyrrolidinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 205-207°C; 3-benzyliden-6-N-[(l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
3-benzyliden-6-N-(N<1>,N'-dietylamino-acetyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 191-193°C; 3-benzyliden-6-N-(N'-isopropylamino-acetyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-benzyliden-6-N-[(4-etoksykarbonyl-l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, sm.p. 250-252°C;
3-benzyliden-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, sm.p. 241-244°C; 3-benzyliden-6-N-[3 -(1-pyrrolidinyl)-propanoyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-benzyliden-6-N-[3 -(4-metyl-l-piperazinyl)-propanoyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-benzyliden-6-N-[3-(4-etoksykarbonyl-l-piperazinyl)-propanoyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on;
3-benzyliden-6-N-[3-(4-ety1-1-piperazinyl)-propanoyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-benzyliden-6-N-[3-(1-piperazinyl)-propanoyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; og 3-benzyliden-6-N-[(4-fenyl-1-piperazinyl)-acetyl]-amino-1,2,3 ,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on.
Eksempel 15
Ved å gå frem ifølge eksempel 14 ut fra egnet substituerte benzylidenderivater ble følgende forbindelser fremstilt: 3-(2-metyl-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
3-(3-metyl-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on;
3 -(4-metyl-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-
tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(2-metoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(3-metoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(4-metoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(4-fluor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(2-klor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(3-klor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(4-klor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(2-etoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(3-etoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(4-etoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolof 2,l-b]kinazolin-9-on; 3-(2,3-dimetoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(3,4-diklor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(2,3-dimetoksy-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(2-metoksy-3-etoksy-benzyliden)-6-N-morfolinoacetyl-amino-1, 2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(2,6-diklor-benzyliden)-6-N-morfolinoacetyl-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(3-klor-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(3-metyl-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(2,6-diklor-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3 -(4-metyl-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3-(4-klor-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(3-metoksy-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(4-metoksy-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(3-etoksy-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; 3 -(4-etoksy-benzyliden)-6-N-(3-morfolino-propanoyl)-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3 -(2-metyl-benzyliden)-6-N[(4-metyl-1-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(3-etoksy-benzyliden)-6-N-[(4-metyl-l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3 -(4-metyl-benzyliden)-6-N-[(4-metyl-l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(4-klor-benzyliden)-6-N-[(4-metyl-1-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on; 3-(3-metoksy-benzyliden)-6-N-[(4-metyl-l-piperaz inyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
3-(4-metoksy-benzyliden)-6-N-[(4-metyl-l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
3 -(4-etoksy-benzyliden)-6-N-[(4-metyl-1-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; og
3-(2,6-diklor-benzyliden)-6-N-[(4-metyl-l-piperazinyl)-acetyl]-amino-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on.
Eksempel 16
6-N-trifluoracetyl-amino-3-benzyliden-l,2,3,9-tetrahydro-pyrrolof2,l-b]kinazolin-9-on, sm.p. 320-323°C (1,8 g) ble omsatt med etylbromacetat (2,4 g) i dimetylformamid (75 ml)
i nærvær av vannfri kaliumkarbonat (1,95 g) under omrøring ved romtempratur i 25 timer og deretter ved 60°C i 30 timer. Etter avkjøling, fortynning med isvann og sur-gjøring med eddiksyre, ble presipitatet filtrert og vasket med vann. Krystallisering fra Cr^C^-metanol ga 6-N-etoksykarbonylmetyl-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo [ 2 , 1-b ] kinazolin-9 -on , sm.p. 222-224°C (1,2 g) som ble oppløst i dimetylformamid (70 ml) og behandlet med 2N NaOH (7,5 ml) ved romtempratur i 3 timer. Fortyning med aceton ga et bunnfall, N-karboksymetyl-amino-3-benzyli-den-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, natriumsalt, sm.p.<>>300°C', som ble filtrert, oppløst i vann og behandlet med eddiksyre. Filtrering av bunnfallet og rensing med eddiksyre ga 0,6 g 6-N-karboksymetyl-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on, sm.p. 290-293°C.
Ved å gå frem på samme måte ble følgende forbindelser fremstilt: 6-N-(2-karboksy-etyl)-amino-3-benzyliden-1,2,3,9-tetrahydro-pyrrolo [ 2,1-b]kinazolin-9-on;
6-N-karboksymetyl-amino-3-(3-metyl-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
6-N-kårboksymetyl-amino-3-(3-etoksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on,•
6-N-kårboksymetyl-amino-3-(4-metyl-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
6-N-karboksymetyl-amino-3-(4-etoksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on;
6-N-karboksymetyl-amino-3-(3-metoksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on;
6-N-karboksymetyl-amino-3-(4-metoksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on;
6-N-karboksymetyl-amino-3-(2,6-diklor-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-9-on; og 6-N-karboksymetyl-amino-3-(4-klor-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on.
Eksempel 17
N-(9-okso-1,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre, etylester, sm.p. 198-200°C (1,2 g)
ble omsatt med benzaldehyd (0,84 g) i metanol (20 ml) i nærvær av natriummetoksyd (0,86 g) under omrøring ved 60°C
i 6 timer. Etter avkjøling ble reaksjonsblandingen konsentrert i vakuum og fortynnet med etyleter; bunnfallet ble filtrert, vasket med eter og oppløst i vann. Surgjøring med eddiksyre ga et bunnfall som ble filtrert og vasket med vann: krystallisering fra maursyre ga 0,4 g N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazolin-6-yl)-amino-oksoeddiksyre, sm.p. 220-225°C.
Eksempel 18
6-nitro-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on (10 g) ble omsatt med 4-karboksy-bensaldehyd (7,78 g) i metanol (4 00 ml) i nærvær av natriumetoksyd (8,2 g) under omrøring ved 60°C i 7 timer. Etter avkjøling ble bunnfallet filtrert av og vasket med metanol og deretter oppløst i vann. Den vandige oppløsning ble gjort sur med eddiksyre og bunnfallet ble filtrert og vasket med vann; krystallisering fra dimetylformamid ga 3-(4-karboksy-benzyliden)-6-nitro-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 299°C dek. (7,6 g), som ble suspendert i dimetylformamid (1050 ml) og omsatt med metyljodid (6,7 g) i nærvær av vannfrif^CO^(4,95 g) under omrøring ved romtemperatur i 3 timer. Reaksjonsblandingen ble fortynnet med isvann og bunnfallet ble filtrert og vasket med vann til nøytral tilstand, hvorved man oppnådde 3-(4-metoksykarbonyl-benzy-liden)-6-nitro-l,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 264-266°C (7,8 g), som ble omsatt med SnCl2.2H20 (23 g) i eddiksyre (275 ml) og 35 %HCl (53 ml) under om-røring ved 60°C i 2,5 timer: etter avkjøling ble bunnfallet filtrert av og vasket med 2N HCl og vann og fint dis-pergert i 2N NaOH. Bunnfallet ble filtrert og vasket med vann til nøytral tilstand og man oppnådde 6-amino-3-(4-metoksykarbonyl-benzyliden)-1,2,3,9-tetrahydro-pyrrolo-
[2,l-b]kinazolin-9-on, sm.p. 292-295°C (5,9 g), som ble behandlet med 35% HCl (120 ml) i eddiksyre (240 ml) under omrøring ved 100°C i 4 timer. Etter avkjøling ble bunnfallet filtrert og vasket med aceton og man oppnådde 6-amino-3-(4-karboksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo [ 2 , 1-b ] kinazolin-9 -on , hydroklorid, sm.p. 295-300°C (5,2 g) som ble suspendert i vann og behandlet med Na2HP04til pH lik 6; bunnfallet ble filtrert og vasket med vann og man oppnådde 6-amino-3-(4-karboksy-benzyliden)-1,2,3,9-tetrahydro-pyrrolo[2,1-b]kinazolin-9-on, sm.p. 336-339°C (44,9 g) som ble omsatt med maleinsyreanhydrid (7,8 g) i dimetylacetamid (50 ml) ved 100°C i 6 timer. Etter avkjøling og fortynning med isvann ble bunnfallet filtrert av og vasket med vann. Krystallisering fra dimetylformamid-metanol ga 3,2 g (Z)-3-{N-[3-(4-karboksy-benzyliden)-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,l-b]kinazo-1ing-6-yl]-aminokarbonyl}-2-propensyre.
NMR (CDCl3-CF3COOD) S ppm: 3,63 (M) (2H, C-2-protoner), 4,68 (T) (2H, C-l-protoner), 6,60 (D) og 6,83 (D) (2H,
a- og6-propenoylprotoner), 7,65-8,55 (M) (5H, -CH= og fenylprotoner).
Ved å gå frem på analog måte ble følgende forbindelse fremstilt: (Z)-3-{N-[3-(4-karboky-benzyliden)-9-okso-1,2,3,9-tetra-hydro-pyrrolo[2,1-b]kinazolin-6-yl]-aminokarbonyl}-2,3-diklor-2-propensyre.
Eksempel 19
(Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl]-2-propensyre (1 g) ble oppløst i kloroform (60 ml) og trietylamin (2,3). Til oppløsningen ble det ved -10°C tilsatt etylklorformat (1,6 ml) og deretter 2-(dietylamino)-etanol (1,5 ml) dråpevis. Reaksjonsblandingen ble holdt ved 0°C i 3 timer og deretter ved romtemperatur i 2 0 timer. Etter vasking med vann ble den organiske oppløsning fordampet i vakuum til tørr tilstand; krystallisering av resten fra diisopropyleter ga
0,6 g (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo [2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, 2-(dietylamino)-etylester.
Ved å gå frem på analog måte ble følgende forbindelser fremstilt: (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, 2-(dimetylamino)-etylester; (E)-3 -[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre, 2-(dietylamino)-etylester; (Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,1-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre , 2-(dietylamino)-etylester; (E)-3-[N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2-propensyre,
2-(dimetylamino)-etylester;
(Z)-3-[N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo-[2,l-b]kinazolin-6-yl)-aminokarbonyl]-2,3-diklor-2-propensyre , 2-(dimetylamino)-etylester;
N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre, 2-(dietylamino)etylester; og N-(3-benzyliden-9-okso-l,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre, 2-(dimetylamino)-etylester.
Eksempel 2 0
Tabletter som hver veide 200 mg og inneholdt 100 mg aktiv substans ble fremstilt som følger:
N-(3-benzyliden-9-okso-1,2,3,9-tetrahydro-pyrrolo[2,1-b]-kinazolin-6-yl)-amino-oksoeddiksyre, laktose og halvparten av maisstivelsen ble blandet, blandingen ble deretter tvunget gjennom en sikt med 0,5 mm åpning. 18 g mais-stivelse ble suspendert i 180 ml varmt vann. Den resulterende pasta ble benyttet for å granulere pulvere. Granulatet ble tørket, forminsket på en sikt med åpning 1,4 mm og deretter ble den gjenværende mengde stivelse, talkum og magnesiumstearat tilsatt, omhyggelig blandet og viderebehandlet til tabletter ved bruk av stanser med diameter 8 mm.
Claims (2)
1. Fremgangsmåte for fremstilling av forbindelser med formelen (I)
m betyr 0 eller 1;
n betyr 1 eller 2;
betyr:
a) hydrogen; C^ -C^ -alkenyl; eller C-^ -C g-alkyl, usubstituert eller substituert med en eller flere substituenter valgt blant halogen, hydroksy og fenyl; eller
b) formyl; eller C2 -Cg-alkanoyl, usubstituert eller substituert med en eller flere substituenter valgt blant halogen, C-^-C^-alkoksy og fenyl;
X fullfører en enkeltbinding eller det represnterer:
a <1> ) en forgrenet eller rett C-^ -C^ -alkylen- eller C2 -C12~
alkylenkjede, usubstituert eller substituert med en eller flere substituenter valgt blant halogen og fenyl;
b') fenylen, usubstituert eller substituert med 1-4 halogenatomer;
c') cykloheksylen eller cykloheksenylen;
R2 betyr;
a") en gruppe - CE^ Z, der Z betyr klor, brom eller jod;
^ R
b") en gruppe -CH_N-^ .n 7, hvori hver av R-, og RQ uavhengig
8
kan være hydrogen eller C^ -C^ -alkyl eller R^ eller Rg,
tatt sammen med nitrogenatomet, danner en usubstituert N-pyrrolidinyl-, morfolino- eller piperidinoring eller en N-piperazinylring som er usubstituert eller substituert med C-^ -C^ -alkyl eller med fenyl eller med C-^ -C^ -alkoksykarbonyl;
C") karboksy eller C^ -C-,-alkoksykarbonyl, usubstituert
eller substituert med en gruppe
der R7 og Rg er som angitt ovenfor;
R^ betyr et hydrogenatom eller en C-^ -Cg-alkylgruppe;
idet hver av R^ , R^ og Rg uavhengig betyr et hydrogenatom
eller et halogenatom, C-^-Cg-alkyl, halo-C-^-C^-alkyl, hydroksy, C-^ -C g-alk ok sy, -C^-alkenyloksy, formyloksy, C^ -Cg-alkanoyloksy, karboksy, C^ -C^ -alkoksykarbonyl, hvori alkoksydelen er usubstituert eller substituert med
en gruppe
der R7 og R„ er som angitt ovenfor,
nitro eller en gruppe
, der hver av Rg og R^ q uavhengig betyr et hydrogenatom, en C-^-Cg-alkylgruppe, formyl eller C-,-C0-alkanoyl; eller hvilke som helst ved siden av hverandre stående R^ , R^ og Rg, tatt sammen, danner en C-^-C^-alkylendioksygruppe; og farmasøytisk akseptable salter derav,
karakterisert ved at fremgangsmåten omfatter:a) omsetning av en forbindelse med formel (II)
n, R^ , R^ , R^ , R5 og Rg er som angitt ovenfor, med en forbindelse med formel (III)
hvori
X og R2 er som angitt ovenfor og Y betyr et halogenatom, hydroksy eller en gruppe -OCOORg, hvori Rg betyr benzyl, fenyl eller C^ -C^ -alkyl, for således å oppnå en forbindelse med formel (I ) hvori m er 1, eller
b) å omsette en forbindelse med formel (II) som angitt
ovenfor med en forbindelse med formel (IV)
hvori
X er som angitt ovenfor, bortsett fra en enkeltbinding, for å oppnå en forbindelse med formel I, hvori m er 1,
R- er karboksy, og X er som angitt ovenfor, bortsett fra en enkeltbinding; eller
c) å omsette en forbindelse med formel (II) som angitt ovenfor med en forbindelse med formel (V)
hvori
X, Z og R2 er som angitt ovenfor, for å oppnå en forbindelse med formel (I) hvor m er 0; eller
d) å omsette en forbindelse med formel (VI) hvori
m, n, X, R^ , R^ ogR^ er som angitt ovenfor eller et salt derav, med et aldehyd med formelen (VII)
hvori
R^ , R^ og Rg er som angitt ovenfor; og hvis ønskelig, omdanning av en forbindelse med formel (I) til en annen forbindelse med formel (I) og/eller, hvis ønskelig, omdaning av en forbindelse med formel (I) til et farma-søytisk akseptabelt salt og/eller, hvis ønskelig, omdanning av et salt til en fri forbindelse og/eller, hvis ønskelig, å separere en blanding av isomerer i de enkelte isomerer.
2. Fremgangsmåte ifølge krav 1 for fremstillinger av forbindelser med formel (I), hvori
m er 1 ;
n er |l;
R^ er hydrogen eller C-^ -C^ -alkyl, eventuelt usubstituert
eller substituert med fenyl;
X fullfører en enkeltbinding; eller X er C^ -Cg-alkylen eller
C^-Cg-alkenylen, begge eventuelt substituert med opptil 1-3 kloratomer;
1*2 er piperidinometyl, morf olinometyl, (1-pyrrolidinyl) - metyl eller (1-piperazinyl)-metyl, hvori piperazinylringen eventuelt er substituert med C^ -C^ -alkyl, fenyl eller med C^ -C2 -alkoksykarbonyl; eller er karboksy eller C-^-C,--alkoksykarbonyl, eventuelt substituert med en N,N-dimetylamino- eller en N,N-dietylaminogruppe;
R-, er hydrogen eller metyl;
idet hver av R^ , R^ og Rg uavhengig er hydrogen, fluor,
klor, C^ -C2 -alkyl, hydroksy, C^ -C^ -alkoksy, acetoksy, karboksy eller hvilke som helst to ved siden av hverandre stående R^ , R,- og Rg, tatt sammen danner en metylendioksy
gruppe;
samt farmasøytiske akseptable salter derav.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8222591 | 1982-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO832662L true NO832662L (no) | 1984-02-06 |
Family
ID=10532127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO832662A NO832662L (no) | 1982-08-05 | 1983-07-21 | Fremgangsmaate for fremstilling av benzylidene-pyrrolo(2,1-b)quinazoliner og benzyliden-pyrido(2,1-b)quinazoliner |
Country Status (27)
Country | Link |
---|---|
US (1) | US4579847A (no) |
JP (1) | JPS5944388A (no) |
KR (1) | KR840005811A (no) |
AT (1) | ATA270583A (no) |
AU (1) | AU557305B2 (no) |
BE (1) | BE897358A (no) |
CA (1) | CA1212379A (no) |
CH (1) | CH654307A5 (no) |
DE (1) | DE3326511A1 (no) |
DK (1) | DK340083A (no) |
ES (2) | ES8501397A1 (no) |
FI (1) | FI74471C (no) |
FR (1) | FR2531957B1 (no) |
GB (1) | GB2125039B (no) |
GR (1) | GR78650B (no) |
HU (1) | HU188929B (no) |
IL (1) | IL69274A (no) |
IT (1) | IT1194346B (no) |
NL (1) | NL8302642A (no) |
NO (1) | NO832662L (no) |
NZ (1) | NZ204994A (no) |
PH (1) | PH22074A (no) |
PT (1) | PT77092B (no) |
SE (1) | SE461526B (no) |
SU (1) | SU1308197A3 (no) |
YU (1) | YU156283A (no) |
ZA (1) | ZA835288B (no) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106220631B (zh) * | 2016-07-26 | 2019-02-05 | 中山大学 | 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用 |
CA3069745A1 (en) | 2017-08-03 | 2019-02-07 | Galectin Sciences, Llc | Compounds for the prevention and treatment of medical disorders and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3271396A (en) * | 1964-08-17 | 1966-09-06 | Squibb & Sons Inc | Pyrido-quinazoline derivatives |
DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
US4033961A (en) * | 1975-10-07 | 1977-07-05 | Warner-Lambert Company | Pyrido[2-1-b]quinazolin-ones and their methods of preparation |
IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
JPS5942677B2 (ja) * | 1975-12-19 | 1984-10-16 | 中外製薬株式会社 | シユクゴウキナゾリノンユウドウタイノセイホウ |
HU174693B (hu) * | 1976-02-12 | 1980-03-28 | Chinoin Gyogyszer Es Vegyeszet | Sposob poluchenija kondensirovannykh proizvodnykh pirimidina |
US4066767A (en) * | 1976-11-01 | 1978-01-03 | Warner-Lambert Company | 8-(1H-Tetrazol-5-yl)-11H-pyrido[2,1-b]quinazolin-11-ones and method of treating bronchial asthma using them |
DE2739020A1 (de) * | 1977-08-26 | 1979-03-01 | Schering Ag | Pyrido eckige klammer auf 2,1-b eckige klammer zu -chinazolinon-derivate, ihre herstellung und verwendung |
AU527931B2 (en) * | 1979-05-08 | 1983-03-31 | Farmitalia Carlo Erba S.P.A. | Substituted pyrido(1,2-a)pyrimidines |
HU179443B (en) * | 1979-05-11 | 1982-10-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing substituted geminal dihalogeno-derivatives of pyrido-square bracket-1,2-a-square closed-pyrimidines,pyrrolo-square bracket-1,2-a-square bracket closed-pyrimidines and pyrimido-square bracket-1,2,-a-square bracket closed-asepines |
US4423048A (en) * | 1979-11-23 | 1983-12-27 | Pfizer Inc. | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor |
AT377586B (de) * | 1981-06-30 | 1985-04-10 | Erba Farmitalia | Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen |
-
1983
- 1983-07-19 IL IL69274A patent/IL69274A/xx unknown
- 1983-07-19 ES ES524262A patent/ES8501397A1/es not_active Expired
- 1983-07-20 YU YU01562/83A patent/YU156283A/xx unknown
- 1983-07-20 ZA ZA835288A patent/ZA835288B/xx unknown
- 1983-07-20 AU AU17113/83A patent/AU557305B2/en not_active Ceased
- 1983-07-20 FI FI832649A patent/FI74471C/fi not_active IP Right Cessation
- 1983-07-21 NO NO832662A patent/NO832662L/no unknown
- 1983-07-21 GR GR71997A patent/GR78650B/el unknown
- 1983-07-22 CH CH4035/83A patent/CH654307A5/de not_active IP Right Cessation
- 1983-07-22 NZ NZ204994A patent/NZ204994A/en unknown
- 1983-07-22 DE DE19833326511 patent/DE3326511A1/de not_active Ceased
- 1983-07-22 HU HU832600A patent/HU188929B/hu not_active IP Right Cessation
- 1983-07-22 SE SE8304111A patent/SE461526B/sv not_active IP Right Cessation
- 1983-07-25 DK DK340083A patent/DK340083A/da not_active Application Discontinuation
- 1983-07-25 SU SU833624052A patent/SU1308197A3/ru active
- 1983-07-25 KR KR1019830003440A patent/KR840005811A/ko not_active Application Discontinuation
- 1983-07-25 JP JP58134515A patent/JPS5944388A/ja active Pending
- 1983-07-25 NL NL8302642A patent/NL8302642A/nl not_active Application Discontinuation
- 1983-07-25 PT PT77092A patent/PT77092B/pt not_active IP Right Cessation
- 1983-07-25 FR FR8312283A patent/FR2531957B1/fr not_active Expired
- 1983-07-25 AT AT0270583A patent/ATA270583A/de not_active Application Discontinuation
- 1983-07-25 BE BE0/211222A patent/BE897358A/fr not_active IP Right Cessation
- 1983-07-25 CA CA000433127A patent/CA1212379A/en not_active Expired
- 1983-07-25 GB GB08319929A patent/GB2125039B/en not_active Expired
- 1983-07-25 PH PH29278A patent/PH22074A/en unknown
- 1983-07-27 IT IT22255/83A patent/IT1194346B/it active
-
1984
- 1984-01-23 ES ES84529074A patent/ES8505361A1/es not_active Expired
- 1984-12-14 US US06/681,694 patent/US4579847A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2107479C (en) | Pyrazolo[1,5-a]pyrimidine derivatives and anti-inflammatory agent containing the same | |
NO154522B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinolinderivater. | |
AU702587B2 (en) | New heterocyclic spiro compounds, process for the preparation thereof,and pharmaceutical compositions containing them | |
SE444938B (sv) | 5-karboxi-2h-bensofuran-3-on-derivat | |
US4515980A (en) | Substituted aminobenzoates, their preparation and use | |
US3227716A (en) | Therapeutically-active dibenzocycloheptane derivatives | |
CA2010217C (en) | Aralkylamine compounds | |
AU584118B2 (en) | 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof | |
NO164899B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylindolforbindelser. | |
NO832662L (no) | Fremgangsmaate for fremstilling av benzylidene-pyrrolo(2,1-b)quinazoliner og benzyliden-pyrido(2,1-b)quinazoliner | |
US3873538A (en) | Amino-9,10-dihydro-9,10-dioxo-2-anthroic acids | |
IE55377B1 (en) | 1,5-diphenylpyrazolin-3-one compounds,method for preparing them,and pharmaceutical compositions containing these compounds | |
FI72516B (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva 3,6-disubstituerade 2-cyklopropyl-kromoner. | |
CA1219869A (en) | Condensed benzopyrone derivatives | |
US4243665A (en) | 2-Heterocyclylalkyl-6-methoxy-naphthalenes | |
CA1084924A (en) | 4-substituted derivatives of pyrazolo 1,5- a quinoxaline-3-carboxylic acids and esters | |
US4521419A (en) | Condensed cycloaliphatic derivatives of substituted pyrido[1,2-a]pyrimidines and methods of treating allergic conditions, peptic ulcers and inhibiting gastric acid secretion with them | |
US3418317A (en) | 1h-2,3-benzoxazine-4(3h)-one and its 3- and/or 6-substituted derivatives | |
GB2186570A (en) | 9,10-dihydro-phenanthrene derivatives | |
US4629735A (en) | Compositions containing substituted aminobenzoates and use thereof as inhibitors of lipoxygenase | |
AU607866B2 (en) | LO/CO inhibiting benzoxazolones | |
GB2055797A (en) | 2-[(Trimethoxy-phenyl)-cyclopropyl]-chromone derivatives and process for their preparation | |
DK156432B (da) | 3-n-pyrrolo-5-sulfamoylbenzoesyre-derivater til anvendelse som mellemprodukter ved fremstilling af 3-n-pyrrolidino-5-sulfamoylbenzoesyre-derivater | |
CS268628B1 (cs) | Způsob přípravy N-/2-/2-chlor-10,11-di hydrodibenzo|b,f|thiepin-10-ylthio/ethyl/piperszinů « jejich soli |